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ABSTRACT 
 
Scott D. Neidich: Will influenza vaccination protect obese adults? 
(Under the direction of Melinda A. Beck) 
 
Obesity is a significant public health problem, affecting over one third of the United 
States, and more than one in ten worldwide. Obesity is associated with a number of 
comorbidities including cardiovascular disease, diabetes, and importantly, infection. Influenza 
has been recognized since the 2009 H1N1 influenza pandemic to cause increased severity in 
obesity, however use of influenza vaccine to reduce influenza-related risk has not been studied 
specifically in the context of obesity. 
In this dissertation, we report that obese adults are at an increased risk for influenza-like-
illness despite vaccination.  We further report that this deficiency is not due to impairments in 
response to influenza vaccination, as subjects with confirmed influenza and influenza-like illness 
produce vaccine-specific antibodies in comparable levels, as assessed by hemaglutination 
inhibition and microneutralization.  
Additionally, we report no apparent defects in influenza-vaccine specific immunoglobulin 
types, suggesting obesity causes no defects in antibody class switching during influenza vaccine 
response in a population of Caucasian female adults.    Strain-specific response was also assessed, 
and obese Caucasian women were found to responds similarly to control populations. Finally, B -
cell populations were not found to be altered in frequency by vaccination or obesity, however 
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expression of the activation marker CD38 was found to be lower on CD38 expressing B-cells from 
obese participants.  
This dissertation calls into serious question the use of antibody measures as correlates 
of protection. If antibodies are indeed major drivers of immunity in influenza vaccination, then 
subjects who presented with clinical influenza or influenza-like-illness should have been 
protected against influenza. But as we report here, healthy weight and obese subjects with 
influenza-like-illness had similar levels of seroprotection assessed by hemaglutination 
inhibition. Taken in combination with elevated risk for influenza-like-illness in obesity, this 
suggests that hemaglutination inhibition antibody’s status as a correlate of protection against 
influenza should be reexamined, especially in context of obesity. 
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CHAPTER I: BACKGROUND AND SPECIFIC AIMS 
 
A. Obesity and Public Health 
A.1: The Burden of Obesity 
Obesity is a growing public concern, affecting 13% of the population worldwide1 and 
35% of United States2 in 2014. Between 2011 and 2012, 8.1% of infants and toddlers under 2 
years of age were found to fit the definition for obesity, compared with 16.9% of children 
between 2 and 18 years of age and 34.9% of adults3. Hispanic infants and toddlers were found 
to have a greater incidence of obesity than non-Hispanic infants, though no other race effects 
were observed at this age. Between 2 and 18 years of age, Hispanic and Black children had a 
greater incidence of overweight and obesity than Caucasian children, and Asian children had 
the lowest incidence of overweight and obesity. No differences were observed for gender 
within this age group. Non-Hispanic Black adults have a greater incidence of obesity than non-
Hispanic White and Hispanic White adults, while non-Hispanic Asian adults had the lowest 
incidence of obesity. Among all adults an estimated two-thirds of adults are overweight or 
obese, and the number of severely obese (BMI>40) is increasing. By most estimates, obesity 
related diseases are now a major burden on the US Healthcare systems, accounting for 4-7% of 
US Healthcare expenditure in 20034, and is estimated to reach 14-16% by 20305. 
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A.2: Comorbidities of Obesity 
 These cost predictions are not for obesity alone, but include a number of co-morbidities. 
Obesity has been linked to cardiovascular disease for over 60 years6, diabetes for over 85 
years7, and dyslipidemia for over 50 years8. Obesity’s contribution to elevated serum lipid 
levels, and subsequent deposition of lipids onto blood vessel walls causing partial blockages 
that can cause myocardial infarctions have been long described. More recent research9 has 
demonstrated  that these plaques are made worse by infiltration of immune cells, which trigger 
inflammation, enlarging and solidifying plaques. This contributes to increased blood pressure, 
which can induce aneurysm or hemorrhagic stroke elsewhere in the circulatory system. 
Obesity’s relationship to diabetes is relatively newer, but nonetheless very well established. 
Through an incompletely understood mechanism, excess nutrient availability causes many cell 
types (including skeletal muscle cells and adipocytes) to become resistant to insulin, causing a 
feed-forward mechanism with greater circulating levels of glucose. This elevated glucose level 
then contributes to inflammation systemically10. Other diseases including musculoskeletal11, 
gallbladder12, and certain types of cancers13 also have well established causal relationships with 
obesity, and are likely linked to obesity related inflammation. Those diseases are included in 
these cost estimates mentioned previously14. Notably absent from these projections, however, 
is infection: given what we know about influenza infection, these projections may be 
underestimates.  
A.3: Influenza and Public Health 
 Influenza is already a significant public health burden on its own. Between 1976 and 
2006, influenza killed between 0.4-5.1 per 100,000 annually15. Obesity has been shown to be an 
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independent risk factor for increase in the risk of severe infection and death from influenza16. 
And while influenza vaccination is a moderately effective treatment for preventing pneumonia, 
hospitalization, and death from influenza17, whether or not obesity affects the ability to 
respond to influenza vaccination has not been described prior to our investigation in Specific 
Aim 1. The public health burden of obesity related influenza infections has not been quantified, 
however previous and current research from our lab suggests that a substantial portion of 
influenza’s $16.3 billion annual cost may be attributable to obesity18.  
 
B. Influenza Vaccination and the Immune System 
 There are two main forms of influenza vaccination: Live Attenuated Influenza Vaccine 
(LAIV), and the Subunit/Conjugate Influenza Vaccine, referred to in this dissertation as either 
TIV (Trivalent) or QIV (Quadrivalent). In both vaccination strategies, global circulating cases of 
influenza are observed and modeled in order to anticipate which influenza strains are likely to 
be predominant during the coming influenza season. Similar strains are then selected as the 
targets for the annual vaccination, and enter vaccine production. When matched accurately, 
they will induce generation of antibodies to the circulating strain of influenza, protecting those 
inoculated from circulating strains. But even when matched poorly, antibodies and cellular 
immunity generated may also be “cross reactive,” potentially granting some protection against 
circulating strains despite the poor match. 
Influenza virus for vaccine production are typically grown by infecting embryonated chicken 
eggs, however cell culture approaches are also in use19 and may become more prominent in 
the future.  
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B. 1: Vaccine Production 
  For LAIV vaccine production, the influenza strains of interest are reasserted with a cold-
adapted strain and used to infect eggs. influenza infected eggs are incubated at a lower 
temperature of 33 degrees Celsius, and reassortment causes the strain to lose its ability to 
effectively replicate in cells at higher temperatures 20. Patients are inoculated with the 
attenuated viral vaccine intranasally, thereby infecting the epithelia of the upper respiratory 
tract. While the virus will be able to infect cells in the cooler, upper airway, it is unable to 
replicate in the warmer cells of the lower airway, thus preventing a severe infection in healthy 
patients. As LAIV provides a “natural infection” route, it was previously thought to be 
particularly effective in children who may not have been exposed to any influenza virus 
before21. While some researchers found greater vaccine response from LAIV in children, longer 
term epidemiological analysis later suggested that LAIV is actually less effective at preventing 
certain strains of influenza infection, and equally effective for others22. LAIV is therefore no 
longer listed as the preferred vaccination form for children, however parents often select LAIV 
over TIV because it does not require administration via injection.  The same features of LAIV 
previously thought to make it ideal for children also make it potentially harmful to patients 
with immunosuppression, including HIV positive patients. Additionally, neutralizing antibodies 
present in the nasal epithelia from previous exposure may prevent the cold adapted virus from 
initiating a mild infection, preventing “boosting” of the immune system in subjects with a 
history of influenza exposure. This means that elderly subjects, and even adults, may not 
generate additional protection to LAIV. For these, TIV is the preferred vaccination strategy for 
adults and the patients with immunosuppression, and LAIV’s contraindications includes adults 
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over 50 years of age. 
  TIV consists of viruses grown at 37 degrees Celsius, however the virus undergoes a 
subjugation process which cleaves the virus particles into subunits, which are later included in 
the vaccine. TIV is administered through intramuscular injection, typically into the deltoid 
muscle. It is worth noting that the influenza virus is only able to replicate if it reaches the 
respiratory mucosa and is intact, making infection from TIV impossible. 
B.2: Primary and Secondary Response to Vaccination 
 The immune system response to vaccination with TIV or LAIV, and influenza infection 
functions in much the same way. Resident dendritic cells engulf the pathogen or antigen and 
digest it within intracellular vesicles. Antigens induce signals on specialized receptors on the 
surface of these vesicles known as Toll-Like Receptors (TLRs), which induce signaling that alters 
the behavior of the cells. Macrophages typically respond to antigens by becoming more 
inflammatory, seeking out other nearby pathogens more aggressively, and secreting pro-
inflammatory cytokines that induce swelling and inflammation at the site of antigen exposure. 
This inflammation, combined with additional intracellular TLR signaling, causes resident 
dendritic cells to reprogram from a “seek and destroy” phenotype to an “observe and report” 
phenotype. The dendritic cells begin to present the acquired antigens on surface embedded in 
Major Histocompatibility Complex (MHC) proteins, and cease uptake in preparation for 
migration. Following signaling through the CCR7 receptor, the dendritic cell leaves the tissue 
and migrates to the T-cell zone of the nearest draining lymph node. There, it presents MHC-
antigen to T-lymphocytes. T-lymphocytes express the T-cell Receptor (TCR), and each naïve T-
cell generated has a unique region of the TCR with variable specificity for MHC presented 
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antigens. When a T-lymphocyte with an antigen-specific TCR binds to the dendritic cell 
presented antigen, that T-lymphocyte becomes activated. 
 Meanwhile, dendritic cells also release antigens into the lymphoid space in the vicinity 
of B-lymphocytes, and some antigen may flow freely into the lymph node from surrounding 
tissue. B-lymphocytes are named for the B-cell Receptor (BCR), which has a variable region 
similar to the TCR. But unlike the TCR, the BCR can recognize free peptides, and does not 
require MHC presentation. When a B-lymphocyte’s BCR binds to antigen, the B-lymphocyte will 
engulf the antigen, partially digest it, and present peptides on its surface MHC class II proteins. 
While B-lymphocytes residing in inflamed tissues can undergo activation without further 
stimulation, B-lymphocytes in the lymph nodes will migrate from the B-cell zone to the T-cell 
zone, and seek an activated cognate T-lymphocyte: One which shares influenza specificity.  
 When an activated cognate T-cell encounters a B-cell, which it recognizes by 
presentation of antigen, the T lymphocyte provides activation signals including CD40L and 
cytokines including IL-423. This stimulation and costimulation triggers a series of intracellular 
signals that ultimately results in the B-cell activating the AICDA gene and producing the 
Activation-induced Cytidine Deaminase protein (AID). This B-cell, which has some BCR 
specificity for influenza, uses AID to induce mutations to the BCR. Known as somatic hyper 
mutation, this process causes changes to the BCR that may induce greater, lesser, or equivalent 
affinity to the target antigen. The B-cell migrates into the dark zone of a lymph node, along with 
its cognate T-cell. Both multiply, and daughter B-cells compete for limited antigen availability 
on follicular dendritic cells within the germinal center. B-cells with the greatest affinity for 
antigen outcompete B-cells with lesser affinity, a micro-evolutionary event which produces 
7 
 
greater specificity B-cells over the course of a few cell generations. B-cells with lower affinity 
fail this competition for antigen, and undergo apoptosis. 
 The T-cells also undergo a similar process in a separate lymph node compartment. By 
the time the B-cells have completed affinity maturation, a population of cognate T-helper cells 
are ready to help the high-affinity B-cells. These T-helper cells can provide signals to the B-cells 
to undergo class switching and additional proliferation, allowing the B-cell population to expand 
and change their BCR’s to the ones most relevant for the target antigen, which are reviewed 
section B.3. 
 A secondary response to antigen occurs when an antigen previously seen by the 
immune system is introduced, and can happen much more quickly. Secondary exposures to 
previously experienced antigens may not even require a reaction to occur, as long-lived plasma 
cells in the bone marrow secrete antibodies for their entire lives. If the pathogen a vaccine is 
made to protect against manages to get into the body, it may be quickly neutralized by 
circulating levels of antibody and never begin infecting cells, nor illicit an immune reaction. 
Should there be enough pathogen to make it through this layer of protection, circulating 
memory B and T cells will become activated upon antigen exposure in much the same way as in 
a primary infection, and quickly give rise to the same populations. Because the memory cells do 
not need to undergo gene editing, and because there are more circulating pathogen-specific 
memory cells than there were pathogen-specific naïve cells originally, the memory cells are 
able to give rise to a larger population of effector cells more quickly than in the primary 
reaction. This quicker response typically overwhelms the infectious agent, and also generates 
new memory cells for future exposures.   
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B.3: Antibody Classes 
 Depending on the context of the exposure, and the types of antigens present, T-helper 
cells and intracellular TLRs provide different signals to the newly activated B-cells. These signals 
trigger the B-cells to make one final modification to the BCR. In its  secreted form, the BCR is 
more commonly referred to as an immunoglobulin or antibody, and there are multiple forms 
serving multiple purposes. All naïve B-cells express two types of immunoglobulins: 
Immunoglobulin-D (IgD) and Immunoglobulin-M (IgM). While naïve B-cells express these 
immunoglobulins on their surface, they can also be secreted by plasmablasts and plasma cells . 
While IgD’s function has remained largely a mystery since its’ 1965 discovery, recent evidence 
suggests that IgD may recruit basophils to induce inflammatory factors including cathelicidin, 
pentraxin-3, IL-1, IL-2, and BAFF24. These factors upregulate proteins with antimicrobial, 
opsonization, and immune-stimulation functions. Meanwhile, IgM’s function is well established 
to be agglutination, opsonization, and complement fixation. Through some combination of T-
cell derived cytokines, toll-like receptor signaling and possibly other unknown mechanics, B-
cells recombine the heavy chain elements of their immunoglobulin genes to change from 
IgM/IgD coexpression to expression of solely IgM, solely IgD, or solely one of the other 
immunoglobulin subtypes. 
 Viral particles typically illicit an Immunoglobulin-G (IgG) subtypes 1 (IgG1) and 3 (IgG3), 
although it is interesting to note that they are derived from opposing cytokines. IL-4 secreted 
from Th2 cells drives IgG1 class switching and inhibits IgG3, while IFN-gamma drives IgG3 and 
inhibits IgG1. The anti-inflammatory, T-regulatory derived IL-10 promotes both IgG1 and IgG3 
class switching. Both IgG1 and IgG3 effectively activate the complement receptor C1q, leading 
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to greater C3b recruitment and even disruption of any associated bilipid membranes by the 
complement pathway25. For a bacterium or viral (including influenza) infected cell, this can 
mean destruction. IgG1 and IgG2 also effectively bind many Fc receptors, while IgG3 has the 
greatest affinity. 
IgG2 inducement is not fully explained by cytokines or any particular class of T-cells in 
humans, although it does have a complex interaction involving IL-6, wherein the cytokine 
appears to both26 upregulate and downregulate IgG2. IgG2 is typically seen in context of 
bacterial antigen and in response to bacterial polysaccharides, whereas  IgG4 is found with 
chronic exposure to the same antigen, alongside Immunoglobulin-E (IgE).  In contrast to IgG1 
and IgG3, IgG2 and IgG4 have much lower C1q binding affinity and Fc receptor affinity, making 
them less potent drivers of inflammation. Neither is typically observed in response to influenza 
vaccination27. 
In mucosal infections and exposures, IgA has a unique distribution mechanism. While 
other immunoglobulins are produced by B-cells and then diffuse through circulation and lymph, 
IgA interacts with the polymeric immunoglobulin receptor of mucosal epithelial cells, which 
bind IgA and transport it into mucosal spaces. There, IgA neutralizes pathogens, but does not 
trigger inflammation due to an inability to fix complement. While the specific regulation of IgA 
class switching is not fully known, T-cell derived TGFB1 and CD40L play a crucial role in class 
switching28. IgA secretion into mucosal spaces may prevent LAIV from successfully triggering an 
immune response, and is one of the reasons behind that vaccine’s contraindication in adults 
over 50 years of age. 
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C. Obesity and the Immune System 
C.1. Adipose tissue as an immunomodulatory endocrine organ. 
 Obesity is characterized by an excess amount of adipose tissue, which is composed of 
adipocytes, macrophages, lymphocytes, fibroblasts and endothelial cells.  Obesity induces not 
only increased adipocyte number through enlargement of the tissue, but increased adipocyte 
size. Immune cell infiltration is also increased, further adding to the adipose-tissue population. 
In addition to excess adipose tissue, obesity is characterized by an increase in pro-inflammatory 
immune cells, which secrete cytokines that have been shown to promote insulin resistance29. 
Although the exact timing and series of events leading to adipose inflammation in obese 
humans is not known, work in animal models has demonstrated that, as adiposity increases, 
neutrophils enter the adipose tissue first, followed by macrophages, and then T and B cells 30. 
How much of the inflammation is induced by feeding a high fat diet vs. the actual obesity is 
unresolved, although likely both contribute to the inflammation. Indeed, mice that become 
obese on a low-fat chow diet develop similar immune dysfunction compared with obese mice 
fed a high fat diet31.  
      In addition to increased cellular infiltrate into the adipose tissue, the phenotype of the 
immune cells is altered. Macrophages of the M2 type (anti-inflammatory, tissue repairing) 
become more M1 like (pro-inflammatory).  T cells infiltrating the adipose tissue display 
activation markers32 and T regulatory populations are increased within adipose tissue. 
In addition to their role as a storage site for lipids, adipocytes secrete a variety of 
adipokines, including leptin and adiponectin. Although leptin and adiponectin are primarily 
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known for their roles in regulating food intake, body weight and metabolism, it has recently 
become clear that they also play a role in T cell regulation. 
 Leptin is a 16kD adipokine which is secreted directly in proportion to adipocyte mass, 
thereby increasing adiposity causes an increase in leptin levels. Leptin is a well-known regulator 
of food intake and energy expenditure, and more recently has received attention for its pro-
inflammatory characteristics33. Leptin concentration in the blood for healthy weight adults 
typically ranges between 10 and 20 ng/mL and can fluctuate within this range based on food 
intake.  In obesity, however, a greater volume of adipose tissue alters serum leptin levels. 
Average leptin concentration is reported to be over 30 ng/mL in obese humans, and is less 
responsive to dietary fluctuations34. Obese humans can be considered to be in a constant state 
of hyperleptinemia. Hyperleptinemia promotes T-effector cell function while inhibiting T 
regulatory cell function35, whereas absence of leptin prevents T-cell activation. B cells live 
longer in the presence of leptin, and are more resistant to apoptosis 36. Dendritic cells activate T 
cells more strongly in presence of leptin37, and natural killer (NK) cells experience greater 
metabolism and are more cytotoxic with increasing leptin38.  
Leptin induces effects within a cell by binding to a specific cellular receptor, the OB-R 
leptin receptor, and transducing a signal into the cell through protein kinase and phosphatase 
cascades39. Which cascades are activated determines the cell’s response to leptin, however, it is 
important to note that multiple isoforms of the OB receptor exist, each with specific effects. 
Expression of different OB receptors on different cells allows cells to respond in different ways 
from one another36. There are six known isoforms including four short, cell embedded isoforms 
(OB-Ra, OB-Rc, OB-Rd, and OB-Rf) and one long, cell embedded isoform (OB-Rb). Additionally, 
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there is one soluble form (OB-Re).  The soluble OB-Re regulates circulating concentrations of 
leptin and cannot transduce signals into the cell. The short form leptin receptors are mainly 
involved in leptin transport throughout the body, although some intracellular signaling has 
been observed from some of these isoforms. The long-chain OB-Rb is the primary receptor 
involved in signal transduction, thanks to an enlarged intracellular region of the protein which 
facilitates signal transduction through multiple kinase pathways reviewed in Allison and 
Myers40 (2014).  
 OB-Rb is found not only on the cells of the hypothalamus involved in satiety signaling, 
but in multiple immune cell populations including T and B cells, dendritic cells, monocytes, 
neutrophils, macrophages, and natural killer cells. Given the wide variety of cell types which are 
responsive to leptin, it should come as no surprise that the actual effects of leptin signaling on 
different cell types are varied. For this reason, leptin’s function is pleiotropic. 
  T regulatory cells (Tregs) express the OB-Rb receptor, and their activation is diminished 
by leptin signaling41. Dendritic cells, monocytes, B cells and NK cells are all dependent upon 
leptin signaling for their formation prior to activation, and inflammatory conditions including 
obesity have been shown to divert production of some of these cell types from the bone 
marrow to the periphery42. This shift in origin may lead to a shift in immune population favoring 
macrophages “primed” to become M1. While Tregs are increased in number in adipose tissue, 
Treg frequency is reduced with leptin concentration in humans with auto-immune diseases 
such as multiple sclerosis43. The anti-apoptotic effects observed in B cells functions occurs 
similarly in neutrophils, albeit through different signaling cascades 44 Leptin can also alter the 
metabolism of macrophages45. 
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 Adiponectin behaves in a manner opposite to leptin. It is also secreted by adipocytes, 
but is released during low insulin, high glucagon states such as fasting. Despite being secreted 
from adipose tissue like leptin, adiponectin is significantly decreased in obese humans. Healthy 
weight humans have been shown to have serum concentrations around 12 ng/mL, whereas 
obese humans in the same study were closer to 4 ng/mL adiponectin in the serum 
Adiponectin triggers orexigenic pathways in the hypothalamus, inducing hunger and 
food seeking behavior. It plays a role in generation of adipocytes, and can alter metabolism by 
decreasing gluconeogenesis and increasing glucose uptake. This alteration of metabolism may 
be involved in adiponectin’s ability to reverse insulin resistance in mice46, an effect observed 
independently of obesity and weight loss.  
 Just as adiponectin’s function is opposed to leptin’s on satiety, they share an 
antagonistic relationship for several immune cell types. Interestingly, when at rest, only 1% of T 
cells express adiponectin receptor (Adipo-R) on their surface, retaining the receptor in 
intracellular vesicles, where it is inactive47.Upon activation, the Adipo-R migrates to the cell 
surface, allowing the T cells to respond to adiponectin. When adiponectin signaling occurs, T 
cell activity is dampened by enhancing apoptosis of T effector cells and inhibiting  their 
proliferation48.  
 In contrast, 47% of B cells, 93% of monocytes, and 21% of NK cells express adipo-R on 
their surfaces48. When stimulated through this receptor, B cells secrete a soluble factor which 
impairs T cell migration into inflamed tissues, further diminishing inflammatory responses 49. 
Monocytes undergo a greater degree of apoptosis, and secrete fewer pro-inflammatory 
cytokines when stimulated with adiponectin50. 
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Given the general effects of adiponectin on immune cell types, we can consider 
adiponectin to induce “anti-inflammatory” effects on the immune system. It is important to 
note that, while many of these effects are in opposition to leptin, the balance struck between 
adiponectin and leptin in the behavior of the immune system is non-symmetrical.  Whether this 
brings the immune system to a “pro-inflammatory” or “anti-inflammatory” state is dependent 
not only on the relative abundance of these adipokines, but innumerable other factors 
including presence of infection, availability of metabolic substrate, and likely many others.  
Adiponectin and leptin are far from the only adipokines secreted from adipose tissue, 
although they are the only ones thoroughly established to be regulated by energy balance. 
Other pro-inflammatory adipokines include Interleukin 6 (IL-6), monocyte chemoattractant 1 
(MCP1), chemerin, and Tumor Necrosis Factor α (TNFα).  
While each of these is positively associated with obesity, IL6 is very strongly correlated 
with obesity, and has a very important immunomodulatory role involving Tregs. Tregs are a 
subset of T cells which play an important anti-inflammatory role. Tregs are induced after a 
prolonged inflammation period, and the predominant cytokine causing their induction is TGFβ. 
Following induction, Tregs will dampen inflammatory signals in other CD4+ T cells (Th1, Th2, and 
Th17), causing the T cell response to be suppressed. Many other immune cells, including B cell s, 
dendritic cells and macrophages, depend upon T cell signaling for their inflammatory response, 
placing Tregs at a crucial point in inflammation progression. But in combination with the 
adipokine IL6, naïve T-cells exposed to TGFβ will undergo differentiation into the pro-
inflammatory Th17 cell type, depriving the inflammation site of anti-inflammatory Tregs51. The 
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replacement of anti-inflammatory Tregs with pro-inflammatory Th17 cells cause acute 
inflammation, potentially an over-reaction. 
The adipokines MCP1 and chemerin play important roles in monocyte recruitment to 
adipose tissue. MCP152 and chemerin53 are both associated positively with human obesity.  
Recruitment of monocytes is the first step of adipose-tissue macrophage generation. Adipose 
tissue macrophages have a tremendous impact on the microenvironment of adipose tissue, 
which will be discussed in the next section. TNFα is positively associated with obesity54, 
although it is secreted from pro-inflammatory M1 macrophages55 resident in the adipose tissue. 
TNFα stimulates phagocytosis56, as well as M1 polarization and angiogenesis. 
From leptin’s pro-inflammatory effects, to the lack of adiponectin to dampen 
inflammation, obesity triggers a pro-inflammatory cytokine secretion that results in a persistent 
low-grade inflammatory state.  We speculate that this long term, chronic inflammatory state 
may have an impact on the response to pathogens, although the mechanisms remain 
undetermined. Explanations on the interaction between inflammation and infection outcome 
include damage from an excessive inflammatory response to a delayed immune response57, 
which may allow greater pathogen replication in the lung58. Next, we will discuss how the 
innate immune system is affected by these primary characteristics of obesity. 
C.2. Innate immune cells: local and systemic effects of obesity 
 While the precise origin of obesity’s immunological consequences remains open to 
debate, it is widely held that cells of the innate immune system mediate physiological changes 
present in obesity. In the microenvironment of adipose tissue, macrophage infiltration and 
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polarization to a pro-inflammatory subtype (M1 macrophage) is greatly increased. It remains 
unclear whether increased presence of M1 macrophages is the cause, or merely an important 
step in the creation of the low-grade inflammation characteristic of metabolic syndrome.  
What is clear is the difference in macrophage phenotype. Lean adipose tissues include a 
relatively low number of anti-inflammatory M2 macrophages, which metabolize fatty acids and 
dampen immune activation through secretion of IL10 and TGFβ59.  M2 macrophages tend to be 
dispersed throughout the adipose tissue, and may play a role in wound healing in the event of 
injury60. However, the obese adipose environment recruits and polarizes M1 macrophages to 
five times61 the level of M2 in lean adipose tissue. M1 macrophages utilize glucose as their fuel 
source, and secrete pro-inflammatory molecules including TNFα, IL1β and MCP1. Using glucose 
as a fuel source allows M1 macrophages to generate greater amounts of energy without 
consuming as much oxygen, which may be necessary considering the way M1 macrophages 
distribute.  Unlike M2 macrophages, distribution of M1 macrophages tend to cluster around a 
specific feature, called a crown like structure (CLS). Whether due to hypoxia, inflammation, or 
unmanageable hypertrophy, each dying adipocyte recruits dozens of adipose tissue 
macrophages which degrade the damaged cell and consume its fat content. The M1 
macrophages that facilitate this process share many morphological characteristics with foam 
cells in atherosclerosis, and are believed to contribute to inflammation in a similar feed-forward 
mechanism. To clear lipids from the dead adipocyte, M1 macrophages secrete fatty acids into 
the tissue surrounding the CLS. Paradoxically considering their fuel sources, this may then 
facilitate conversion of M2 macrophages to M1, further shifting the adipocyte macrophage 
population toward the M1 phenotype62. 
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 This shift in macrophage population is  not without consequence. M2 macrophage 
secretion of IL4 and IL10 promotes insulin sensitivity in adipocytes, whereas TNFα secretion by 
M1 macrophages acts locally, diminishing insulin sensitivity in adipocytes and other immune 
cells locally.  And in addition to its feed-forward loop role in recruiting monocytes, MCP1 also 
acts to recruit other immune cells including neutrophils, basophils  and mast cells. While these 
effects are highly pronounced within the adipose tissue, many of the adipokines generated 
have systemic effects when they leave the adipose tissue. Leptin and adiponectin’s endocrine 
effects on satiety have already been discussed, but TNFα63  and IL664 also escapes adipose 
tissue into the bloodstream, contributing to systemic insulin resistance. Macrophages may also 
be the primary drivers behind other immune cell infiltration into obese adipose tissue: 
Neutrophils exhibit elevated activity65 and greater numbers66  in obesity, as do mast cells67. 
Both neutrophils68 and mast cells69 are also established to drive insulin resistance in murine 
models. 
C.3. Adaptive immunity: local and systemic effects of obesity  
 Cells from the adaptive immune system play critical roles in both lean and obese 
adipose tissues. In lean, Th2 and Treg cells provide anti-inflammatory cytokine signals to 
infiltrating monocytes, promoting anti-inflammatory M2 cells. It is the action of these anti-
inflammatory T cells that maintains the inflammation-free environment of lean adipose tissue, 
which promotes insulin sensitivity and a healthy function of the endocrine organ. In obesity, 
however, Tregs and Th2 do not form as readily, and instead Th1, Th17, CD8+ T effector cells, 
and B cells are the predominant adaptive immune cells, which give rise to M1 macrophage 
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polarization, greater inflammation, and the pro-inflammatory state. While the mechanism of 
this transition from anti-inflammatory to pro-inflammatory adipose phenotype in obesity 
remains to be determined, the only question of the adaptive immunity’s role is whether it is the 
cause, or merely a significant contributor.  
 Both in adipose tissue and systemically, Th1 cells generally act in concert with 
macrophage and CD8 T cells to combat intracellular bacteria and viruses, whereas Th2 cells 
promote B cell, eosinophil and mast cell activation, prompting a wide response to a wide array 
of extracellular pathogens including viral, bacterial and fungal. Th17 cells are pro-inflammatory 
and aid in clearing pathogens. 
 However, obesity affects the adaptive immune system beyond its changes to the 
adipose microenvironment as well, which may be attributable, in part, to nutrient availability. 
CD4 T cell subtypes Th1, Th2 and Th17 are glycolytic cell types, and increasing glucose 
availability causes greater T effector function70. While each of these T cell subtypes causes a 
distinct inflammatory response, together they all contribute to inflammation. Conversely, Treg 
cells depend on fatty acid oxidation for their metabolism, and do not increase their anti -
inflammatory effects during increased glucose availability71.  
Given T cell function dependency upon glucose availability, it should come as no 
surprise that T cell activation includes upregulation of glucose transporters. Specifically, T cells 
will become insulin sensitive during activation, and use insulin signaling in a classical manner to 
activate Glut-1. Indeed, activated T cells from hyperglycemic subjects produce greater levels of 
pro-inflammatory cytokines in vitro72 and in vivo. Insulin deficiency due to poor diet or genetic 
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defect results in poor T cell function, increasing susceptibility to infection73. The extent to which 
this can be attributed to insulin resistance remains unclear. 
 While relatively little has been characterized about B cell metabolism and obesity, 
numerous studies have pointed to B cell alterations related to obesity, including greater 
infiltration of mature, class-switched B-cells into visceral adipose tissue74,75 and increasing B-
regulatory cell activity in obese mice has been shown to reduce inflammation74,76. It remains to 
be determined whether these are secondary effects from T cell alterations, distinct effects 
brought on by obesity through B cells directly, or a more complicated mechanism yet to be 
proposed.  
 
D. Viral Infection and Obesity. 
 Obesity is believed to have numerous synergistic effects with viral infections. For 
example, hepatitis C infection combined with obesity induces greater degree of hepatic 
steatosis.77 While both obesity and hepatitis C can cause steatosis on their own, the combined 
effect is more pronounced than either disease individually. But in HIV infection, obesity has a 
complex interaction with the associated disease AIDS. Prior to the advent of anti-retroviral 
therapy (ART), which has effectively turned HIV from a death sentence into a serious, chronic, 
but survivable viral infection, obesity was associated with prolonged lifespan following HIV 
infection. Obesity can lead to greater numbers of CD4+ T helper cells, which are also the cells 
HIV targets.. Therefore, unsurprisingly, obesity is positively associated with CD4+ T cells levels in 
HIV infected adults. Before ART, this also meant greater longevity78. However, ART has been 
shown to exacerbate dyslipidemia by destroying the mitochondria of adipocytes 79, leading to 
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greater occurrence of atherosclerosis in HIV positive adults, especially obese adults 80. So while 
obesity may give some protections against HIV progression, it comes at a greater cost.  
 Obese humans are at a greater risk of hospitalization and death from influenza than 
healthy weight individuals81, and obesity is linked with greater need for mechanical ventilation 
and time spent in the Intensive Care Unit16. While there are changes to the muscular 
involvement of breathing caused by obesity82, the immunological rather than physical 
conditions of obesity are likely to be substantial contributors to complications.  Given previous 
work in our lab, we can speculate on obesity’s effects: Chronic inflammation associated with 
obesity may delay the specific immune response, allowing the infection to become more 
virulent. Alternatively, obesity may cause the immune system to overreact to the infection and 
induce excessive tissue damage, paradoxically causing secondary infection and severe 
pneumonia. Indeed, in obese models of influenza infection, there is greater inflammation in 
lung tissues of obese mice83, likely attributable to diminished Treg activity and increased 
systemic levels of CD4+ T cells. Additionally, despite generating a normal response to influenza 
vaccination initially, higher weight is correlated with a greater decrease in antibody levels 1 
year post vaccination in humans84 suggesting that although the antibody response is not 
acutely affected, obese individuals are unable to maintain the antibody response over time.  
 Influenza virus is not a single, immutable infectious agent: multiple strains which can 
infect humans exist, and immunity—especially humoral immunity—to one strain may not 
equate to immunity to another due to differences in protein composition of the virus. Humoral 
immunity primarily targets external viral proteins, while T-cell immunity primarily responds to 
internal viral proteins, and proteins expressed during the virus’s intracellular replication phase. 
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For this reason, T cells can produce cross-reactive immunity, as, in contrast to external viral 
proteins, internal influenza viral proteins are similar among strains. However, after priming 
obese mice with an influenza H3N2 strain and then re-infecting with what would otherwise be a 
lethal dose of influenza pandemic H1N1, 25% of obese mice die with survivors experiencing 10 
to 100 times greater viral titers in lung tissue, as well as greater pro-inflammatory cytokines. In 
contrast, 100% of lean mice survive85. In humans, T cells isolated from overweight and obese 
humans show diminished markers of activation, while dendritic cells express reduced MHC-II, 
the protein responsible for antigen presentation to T-cells86. Despite these deficits in T-cell 
responses, following vaccination, obese adults produce an antibody response equivalent to 
healthy weight adults,  however the antibody response declines more rapidly84. 
Taken in sum, obesity exacerbates dyslipidemia associated with some infections, inhibits 
memory response to infection, and contributes to a pro-inflammatory environment that 
licenses greater tissue damage from infection and inflammation.  
 
E. Specific Aims 
There remain specific questions unanswered by existing research. While there is ample 
epidemiological evidence that obese individuals are at greater risk for severe illness and death 
from influenza, it has not been determined if vaccination mitigates this disparity. We will 
address this question in Specific Aim 1, where we hypothesize that, compared with vaccinated 
healthy weight adults, obese adults will have a greater risk of influenza infection despite 
vaccination. 
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 Secondly, although obesity’s effects on innate immune cells have been closely studied, 
and the impact on T-cells in the context of influenza infection has been investigated by our 
laboratory, humoral Immunity has not been thoroughly investigated. Presently, published 
literature on influenza and infection is largely limited to T-cell immunity, with only one 
publication assessing vaccination and B-cell response in obese populations to date87, with a 
narrow target focus, small experimental size, and findings that differ substantially from our 
laboratory’s previously published work in antibody variation. Specific aim 2 will expand 
characterization of the B-cell response to influenza vaccination by specifically investigating B 
cell subpopulations and IgG serotypes. Specific Aim 2 is to characterize alterations in humoral 
response to influenza vaccination driven by obesity in humans. We hypothesize that obese 
adults will exhibit impaired memory B-cell numbers despite normal plasma cell generation.
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CHAPTER II: OBESITY DIMINISHES EFFICACY OF INFLUENZA VACCINE IN ADULTS 
 
Overview 
 Influenza infection represents a significant public health problem for the general public, 
and is especially dangerous to individuals with obesity.  Although obesity has been identified as 
an independent risk factor for influenza infection for over 5 years, protection offered by 
vaccination has not been specifically examined in this at-risk population. Here, we used a 
prospective observational study to assess whether influenza vaccination modifies the risk of 
influenza infection associated with obesity. Using multiple measures to assess influenza vaccine 
response, we found that obese adults generate antibodies at least as effectively as healthy 
weight adults. However, despite this equivalent humoral response, when compared with 
vaccinated healthy weight adults, vaccinated obese adults are approximately twice as likely to 
develop clinical influenza infection.  
Introduction 
 Infection with influenza represents a worldwide public health problem, with 15% of the 
global population infected annually. In addition, pandemic outbreaks of influenza can greatly 
magnify the number of infections and death. Historically, the highest risk groups for increased 
morbidity and mortality from influenza infection include the elderly1, the very young88, 
individuals with chronic diseases such as COPD89 or congestive heart failure90, and pregnant 
women91. Recently, obesity has also been recognized as an independent risk factor for 
influenza92. This is significant, because at present 37% of the US population is obese93, and 
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worldwide about 13% of the adult population is obese94. Obesity is defined as excessive adiposity 
as a result of prolonged positive energy imbalance, and is typically defined by Body Mass Index 
(BMI) in excess of 30 kg/m2. 
Vaccination is the best, and currently only, medically available prevention against 
influenza virus infection. Neutralizing antibodies against the two surface proteins of the influenza 
virion, hemagglutinin (HA) and neuraminidase (NA), are generated in response to influenza 
vaccination and are considered to be protective95.  However, year-to-year changes in the HA and 
NA result in the influenza vaccine being less effective in subsequent years, often requiring a yearly 
reformulation of the influenza vaccine. This also means that in the event of a pandemic, in which 
viral reassortment causes major changes in the HA and NA,  there may be little protection, 
contributing to a pandemic spread of the virus96. Generating protection against the most likely 
viruses to be encountered is facilitated by inclusion of three influenza types: typically one 
influenza A virus with Hemaglutinin type 1 and Neuraminidase Type 1 (H1N1), a second Influenza 
A virus with H3N2, and an Influenza B virus are included in the trivalent influenza vaccine. In the 
past several years, a second B virus has been added to make the quadrivalent vaccine. 
The protective effect of influenza vaccine can vary year to year, because its effectiveness depends 
on the antigenic match between the viruses in the vaccine and the strain(s) circulating in the 
community. For example, in the 2014-2015 season a mismatch in the northern hemisphere 
between the H3N2 vaccine strain  and the H3N2 strain circulating in the community reduced 
estimated vaccine effectiveness to 23%97. In contrast, the 2011-2012 year matched correctly and 
achieved protection rates of 39-65% varying by vaccine strain component, and 47% overall98. 
Even with proper matching as in 2011-2012, other factors affecting the general health of vaccine 
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recipients, including age,106 immune dysfunction99, and other uncharacterized factors limit full 
protection including unexplored effects of obesity. 
Vaccine induced-antibody protection against influenza infection is generally assessed by 
quantifying homospecific antibody titer against the HA of viral strains included in the vaccine. In 
addition to homospecific antibodies,  limited hetero- and poly-specific antibodies are also 
observed from prior exposures100 and vaccinations101. Although there is an ongoing research 
effort to generate a universal cross-protective vaccine in which antibodies would be broadly 
cross-reactive101, no such vaccine is currently available. For measuring a successful immunization 
with influenza vaccine, concentrations of antibodies against the HA is conveniently measured.  
HA inhibition assays (HAI) measure anti-HA antibodies; these levels correlate with protection102.  
Seroconversion is defined as a 4-fold increase in antibody titer from pre to post vaccination and 
is considered to be an immunogenic response103. Seroconversion is also considered a measure of 
potential vaccine efficacy. However, older adults have been shown to develop influenza despite 
undergoing seroconversion104, demonstrating that antibody titers do not necessarily translate 
into clinical protection.  
Seroprotection is defined as an HAI above a certain threshold, typically 32 or 40 HAU/50 
µL serum. Seroprotection is more commonly referred to as a correlate of protection than an 
immunogenic marker because pre-vaccination HAI measures often meet this definition 105. 
Despite being considered a correlate of protection, seroprotection suffers the same deficiencies 
as seroconversion in elderly participants. Additionally, seroconversion rates after vaccination 
have been reported as low as 58% in healthy adults, and seroprotection following vaccination 
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has been reported to be as low as 78%106. This suggest that the influenza vaccine fails to illicit 
humoral protection in approximately 1 in 5 healthy recipients 106. 
 We have previously shown that vaccinated obese individuals have an impaired response 
to influenza vaccination86. Although both healthy weight, overweight (BMI between 25 and 30) 
and obese adults developed equivalent levels of HAI antibodies to vaccine strains of influenza at 
30 days’ post vaccination, obese adults failed to maintain this response. At one-year post 
vaccination, greater BMI was associated with a steeper decline in antibody titer. Compared with 
healthy weight individuals, obese individuals were more likely to have a greater than 4-fold drop 
in antibody titer at one year. However, this analysis did not determine whether vaccinated obese 
adults were more likely than healthy weight adults to develop influenza. Here, we demonstrate 
that, compared with healthy weight adults, influenza-vaccinated obese adults had a higher rate 
of laboratory-confirmed influenza and influenza-like illness. Importantly, as has been reported 
for elderly adults, the increase in infection in obese adults occurred with antibody titers 
considered to be protective.  These findings question the validity of HAI as a correlate of 
protection in obese adults, and makes clear that while HAI may still be an effective correlate of 
protection in some populations, it is certainly not the cause of protection. 
 
Materials and Methods 
Subject Population 
Participants were recruited as a part of a prospective observational study carried out at 
the University of North Carolina at Chapel Hill Family Medicine Center, an academic outpatient 
primary care facility in Chapel Hill, North Carolina. Recruitment criteria for this study included 
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adults 18 years of age and older receiving the seasonal trivalent inactivated influenza vaccine 
(IIV) for the years 2013-2014 and 2014-2015, with exclusion for immunosuppression, 
immunomodulatory or immunosuppressive drugs, acute febrile illness, history of 
hypersensitivity to any influenza vaccine components, history of Guillain-Barre syndrome, use 
of theophylline preparations, or warfarin.  
 Trivalent IIV during the 2013-2014 influenza season was formulated on 
recommendations for an A/California/7/2009(H1N1)-pandemic-09-like virus, an 
A/Victoria/361/2011(H3N2) or A/Texas/361/2011(H3N2)-like virus (which are antigenically 
similar), and a B/Massachusetts/02/2012-like virus.  
  Trivalent IIV during the 2014-2015 influenza season was formulated on 
recommendations for an A/California/7/2009(H1N1)-pandemic-09-like virus, an 
A/Texas/361/2011(H3N2)-like virus, and a B/Massachusetts/02/2012-like virus. 
Participants were contacted weekly for 6 months when influenza activity was first 
reported in the community. Participants were contacted by phone or email and asked to report 
any symptoms of fever, cough, runny nose, sore throat, muscle aches, headaches and fatigue to 
assess for influenza symptoms. Medical records of all study participants, whether they reported 
influenza-like symptoms or not, were reviewed at the end of each season for medically 
reported influenza-like illness or laboratory confirmed influenza. In addition to weekly 
calls/emails, participants were also instructed to contact the study nurse if they developed 
influenza-like symptoms. Laboratory confirmed influenza infection was determined from the 
medical records which reported a positive influenza specimen using either PCR or a rapid-
influenza detection system. All participants who tested positive for influenza were diagnosed 
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with influenza A. Influenza-like illness was defined as fever greater than 100 F with a cough and 
in the absence of any other medical diagnosis. For participants who became infected with 
clinically diagnosed influenza, we identified vaccinated controls matched for age, sex, race, 
BMI, that did not report any influenza-like illness during the reporting period. 
 
 
Serum sample collection  
Participants recruited to the study provided a blood sample prior to vaccination and 28-
35 days post vaccination. Blood was collected via antecubital puncture. Sera were collected using 
non-heparinized 10 mL vacutainers, which were allowed to clot at room temperature for 2 hours  
before being separated by centrifugation at 800 x g for 10 minutes.  Sera were then frozen at -80 
C for subsequent analysis. 
Antibody quantification 
Hemaglutination Inhibition assay.  A/California/04/2009 (CA/09, pdmH1N1), 
A/Texas/50/2012 (H3N2)  and A/Switzerland/H3N2 viral stocks were propagated in the allantoic 
cavity of 10-day-old specific pathogen-free embryonated chicken eggs at 37°C. Allantoic fluid 
was harvested, cleared by centrifugation, and stored at -80°C as described previously107. The 
HAI titer was determined in accordance with World Health Organization guidelines 108.  
Microneutralization assay: Madin-Darby Canine Kidney (MDCK) cells were cultured in Eagle’s 
minimum essential medium (MEM, MediaTech, Manassas, VA) supplemented with 2 mM 
glutamine and 10% fetal bovine sera (FBS, Gemini BioProducts, West Sacramento, CA) and 
grown at 37°C under 5% CO2. Sera were treated with receptor destroying enzyme (RDE; Denka 
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Seiken, Cambell California n) and standard microneutralization (MN) were performed according 
to WHO guidelines108. Luminescent microneutralization (MN) assays were performed as 
previously described using a reverse genetics A/California/04/2009 virus containing an NLuc on 
its polymerase segment109. 
 
Statistics 
 Results from surveillance and medical records were analyzed using log-binomial and 
logistical regression in Stata statistical software. Microneutralization and HAI results were 
analyzed via 2-way analysis of variance (ANOVA) in Graphpad Prism Software. A s tatistical 
cutoff of p<0.05 was used. 
 
Results 
Obesity was associated with increased risk of developing laboratory-confirmed and influenza-
like illness.  
Demographics for all participants in 2013-2014 and 2014-2015 influenza participants 
can be found in Table 1 and Table 2, and include a total of 1022 vaccinated adults. During 2013-
2014, 3 participants had laboratory confirmed influenza, 2 of whom were obes e and 1 was 
overweight. This increased to 7 during 2014-2015, with 3 obese, 3 overweight, and 1 healthy 
weight. Although this sample was not large enough to consider greater risk in obese 
participants compared to healthy weight, we did find greater risk when adults with laboratory 
confirmed influenza were considered alongside influenza-like illness. Combined, there were 30 
cases of influenza-like illness during the 2013-2014 seasonal influenza monitoring period, and 
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43 cases during 2014-2015.   The number of combined laboratory-confirmed influenza and 
influenza-like illnesses for both years are reported in Table 3 where obese participants had 
approximately twice the risk for laboratory confirmed or influenza-like illness despite 
vaccination (p=0.0310, 95% CI 1.0156-4.0756).    Additionally, logistic regression of BMI using 
influenza season as a covariate found that although there were more cases during the 2014-
2015 year than in 2013-2014 (p=0.00731), BMI remained a significant predictor of influenza-like 
illness (p=0.00438). Consistent with elevated risk for influenza infection in the elderly106, age 
was correlated with a greater risk (logistic regress ion p=0.0498), however this effect was not 
observed in the larger category of influenza-like illness. Using age as a covariate did not 
eliminate the effect of obesity. 
Antibody response to vaccine and circulating influenza viruses did not predict susceptibility to 
infection. 
 For participants with laboratory confirmed or influenza-like illness, there were no 
differences in HAI pre and post vaccination titers to vaccine strain H1N1 (Figure 1A and B) or 
H3N2 (Figure 1C and D) among healthy weight, overweight, or obese individuals, despite the 
increased risk for the obese individuals to develop influenza or influenza-like illness. However, in 
the 2014-2015 vaccine year, the H3N2 vaccine strain was a poor match for the circulating strains, 
resulting in a vaccine efficacy reported at only 23%97. Therefore, we measured HAI titers against 
the circulating strain of influenza, A/Switzerland/9715293/2013 for al l participants reporting 
laboratory confirmed or influenza-like illness. As we noted for H3N2 vaccine strains, there was 
no difference in HAI titers to the circulating strains among healthy weight, overweight or obese 
adults (Figure 1E and F).  In addition, we examined percent of adults in each weight classification 
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for seroprotection (HAI >40) or seroconversion (>4-fold rise in HAI pre to post). As shown in Table 
4, Obesity did not affect odds of seroconversion or seroprotection. For California/H1N1 and 
H3N2/Texas/50, there were no statistical differences that could explain the higher rate of 
infection in the obese group.    
Comparison of HAI and microneutralization titers between laboratory confirmed influenza 
participants and matched, uninfected controls. 
Differences in antibody responses between laboratory-confirmed influenza infected 
participants and controls matched for age, race, sex and BMI who did not develop influenza 
during the study period were also investigated. Table 5 provides the demographic information 
for the infected participants and their controls. As seen in Figure 2, HAI titers did not differ 
between infected adults and non-infected adults. Influenza-specific antibodies were assessed by 
microneutralization, and again no differences were detected in titers between infected and non-
infected adults (Figure 3) 
DISCUSSION 
This prospective analysis of participants receiving influenza vaccine used a convenience 
sample to monitor influenza and flu-like illness over two influenza vaccination seasons. Obese 
adults were approximately two times more likely than healthy weight participants to present 
with influenza or influenza-like illness, demonstrating that S-IIV does not confer the same levels 
of protection to obese participants. Furthermore, our antibody findings suggest that this is not 
due to lack of immunogenic response to vaccination. Indeed, clinically confirmed influenza 
participants had similar HAI titers to vaccination as controls who did not report symptoms.  
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Of particular interest are findings concerning the 2014-2015 influenza season. That year, 
a mismatch between the H3N2 circulating strain and World Health Organization 
recommendations drove an increase in influenza cases97, however our findings showed that 
participants who were infected with influenza during this season actually had similar levels of 
protective antibodies as defined by HAI. In fact, 68.3% had a protective level (40 HAI or greater) 
against the predominant circulating A/Switzerland/H3N2 strain, calling into question HAI 
antibody’s definition as protective. Although HAI antibodies have been well established as 
correlates of protection, protective HAI levels generated from vaccination against the 
predominant strain clearly demonstrate that HAI antibodies are not solely protective in the 
infected population. The clinically confirmed population in this study was 86% obese or 
overweight, however more data are necessary to determine if HAI antibodies are poorly 
correlated with protection solely in non-healthy weight populations.  
Obesity has been recognized as an independent risk factor for influenza infection for 5 
years, however this is the first study to our knowledge to monitor influenza vaccination and 
subsequent outcomes in obesity prospectively. Without prospective monitoring, studies looking 
at predictors of influenza infection and outcome are unable to determine response to influenza 
vaccine. Although this study would be better informed with unvaccinated controls, for ethical 
reasons, an unvaccinated group was not included. 
In conclusion, this study demonstrates the need for greater influenza vaccination 
monitoring techniques to determine vaccine’s extent of protection in at-risk populations, 
especially the obese. This clinical study provides a framework for future vaccination and risk 
group investigations, and provides justification for the necessity of testing alternative influenza 
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vaccination formulations for use in obese populations. The high-dose vaccine, for example, has 
been shown to induce greater HAI antibody to influenza among adults 65 years age or older110 
and may be a viable candidate for future investigations in obese participants, despite HAI’s 
inability to protect individuals in this study. The newly approved adjuvanted influenza vaccine, 
which consists of inactivated influenza virus and a squalene-oil mixture (MF59)known to induce 
CD4+ T-cell activation111 may be of particular interest in obesity, where CD4+ T-cells have 
previously been shown to be impaired in context of influenza vaccination84, 86, 87. This study 
underscores the importance of immune measures going beyond HAI and microneutralization to 
inform such changes in vaccination recommendations and approvals for influenza. As 
demonstrated here, microneutralizing titers and even HAI against the circulating strain did not 
prevent participants in this study from becoming infected, as has been reported previously for 
elderly populations106. While greater correlation of protection has been observed from 
antibodies inhibiting the other major influenza surface protein, neuraminidase112, our previous 
work has also suggested that T-cell impairment occurs in obese populations86,87 which suggests 
that regardless of humoral antibody generation, other immune considerations should also be 
evaluated as better correlates or even drivers of protection. Given the lack of B-cell derived 
differences between cases and controls seen here, and T-cell’s role as critical immune drivers of 
the entire immune system, T-cell related correlates of protection should be prioritized in 
exploring alternative correlates of protection.  
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Table 1: 2013-2014 Influenza Season 
Enrollment  
Underweight Healthy weight Overweight Obese Total 
 
 Enrolled 6 (1.0) 143 (24.9) 170 (29.6) 256 (44.5) 575(100) 
 Age* 53.0 ± (19.9) 55.8 ± 18.3 53.5 ± 16.2 54.1 ± 12.2  
Gender 
 Male 3 (0.5) 53 (9.2) 73 (12.7) 75 (13.0) 204 (35.5) 
 Female 3 (0.5) 90 (15.7) 97 (16.9) 181 (31.5) 371 (64.5) 
Race 
 Caucasian 6 (1.0) 103 (17.9) 115 (20.0) 140 (24.3) 364 (63.3) 
 African American  24 (4.2) 43 (7.5) 108 (18.78) 175 (30.4) 
 Other  16 (2.8) 12 (2.1) 8 (1.4) 36 (6.3) 
Diabetes 
 Yes- Type 1  3 (0.5) 1 (0.2) 1 (0.2) 5 (0.9) 
 Yes- Type 2  11 (1.9) 30 (5.2) 86 (15.0) 127 (22.1) 
 Pre-Diabetes 1 (0.2) 7 (1.2) 10 (1.7) 29 (5.0) 47 (8.2) 
 No 5 (0.9) 122 (21.2) 129 (22.4) 140 (26.3) 396 (68.9) 
Table 1: Demographics for the 2013-2014 seasonal enrollment. *Age is reported as average as average at day of years (standard deviation). All other values are number of 
participants (percent makeup of total). 
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Table 2: 2014-2015 Influenza Season 
Enrollment Underweight 
Healthy 
weight Overweight Obese Total 
     
 Enrolled 6 (1.3) 134 (30.0) 112 (25.1) 195 (43.6) 447 (100) 
 Age* 54.4 ± 20.9 54.1 ± 18.6 59.4 ± 16.7 54.4 ± 13.6  
Gender 
 Male 2 (0.4) 45 (10.1) 54 (12.1) 56 (12.5) 157 (35.1) 
 Female 4 (0.9) 89 (19.9) 58 (13.0) 139 (31.1) 290 (64.9) 
Race 
 Caucasian 3 (0.7) 98 (21.9) 74 (16.6) 112 (25.1) 287 (64.2) 
 African American  20 (4.5) 33 (7.4) 74 (16.6) 127 (28.4) 
 Other 3 (0.7) 16 (3.6) 5 (0.9) 9 (2.0) 33 (7.4) 
Diabetes 
 Yes- Type 1   1 (0.2) 2 (0.4) 3 (0.7) 
 Yes- Type 2  9 (2.0) 19 (4.3) 57 (12.8) 85 (19.0) 
 Pre-Diabetes 1 (0.2) 2 (0.4) 7 (1.6) 18 (4.0) 28 (6.3) 
 No 5 (1.1) 123 (27.5) 85 (19.0) 118 (26.4) 331 (74.0) 
Table 2: Demographics for the 2014-2015 seasonal enrollment. *Age is reported as average as average at day of years (standard deviation). All other values are number of 
participants (percent makeup of total). 
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Table 3: Influenza-Like Illness during 2013-2015 Flu Seasons 
 
  Underweight Healthy Weight Overweight Obese 
  
Total 
2013-
2014 
Laboratory confirmed influenza - 1 1 1  3 
Influenza-like Illness (excludes 
confirmed) - 4 6 17 
 27 
No Flu-like Illness 6 138 163 238  545 
        
2014-
2015 
Laboratory confirmed influenza - 1 3 3  7 
Flu-like Illness (excludes 
confirmed) - 8 6 22 
 36 
No Flu-like Illness 6 125 104 169  404 
        
Total  12 277 282 451  1022 
Odds Ratio vs Healthy Weight 1.40 1 1.13 1.98   
95% CI (0.04-12.90) (0.47-2.14) (0.54-2.35) (1.06-3.40)   
Significance n.s. n.s. n.s. *   
               
 
Table 3: Summary of which participants acquired influenza during the subsequent season. Data incorporates participants from  both 2013-2014 and 2014-2015. *Obese 
vaccinated participants were at a significantly greater risk of Flu-like illness (Odds ratio=2.03, 95% CI 1.02-4.08 p=0.0451). Note: Underweight participants are not included on this 
table. 
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Table 4: Seroconversion among influenza-like Illness during 2013-2014 and 2014-2015 
 
 A/California/09/H1N1 A/Texas/50/H3N2 A/Switzerland/H3N2 
 
Seroconversiona 
Odds 
Ratio Seroprotectionb 
Odds 
Ratio N Seroconversiona 
Odds 
Ratio Seroprotectionb 
Odds 
Ratio N Seroconversiona 
Odds 
Ratio Seroprotectionb 
Odds 
Ratio N 
Healthy 
Weight 41.67% ns 66.67% ns 12 33.33% ns 66.67% ns 12 75.00% ns 62.50% ns 8 
Overweight 42.86% ns 64.29% ns 14 35.71% ns 78.57% ns 14 55.56% ns 100.00% ns 9 
Obese 40.54% ns 70.27% ns 37 51.35% ns 89.19% ns 37 33.33% ns
c 
 58.33% ns 24 
                
Combined 41.27%  68.25%  63 44.44%  82.54%  63 46.34%  68.29%  41 
Table 4: Seroconversion and Seroprotection rates in participants who presented with Influenza-like illness. Data are shown as percentage of data points.  Only participants from 
2014-2015 were assessed for A/Switzerland/H3N2. Data from 10 subjects were not analyzed for pH1N1 and a/Texas/50/H3N2, including one eligible for A/Switzerland/H3N2 
analysis. a: Seroconversion is defined as 4-fold or greater increase in HAI. b: Seroprotection is defined as HAI>40 at 30 days post vaccination. c: Seroconversion was insignificantly 
lower in obese subjects compared with healthy weight, p=0.0525. 
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Table 5: 
Demographics of 
Case-confirmed 
Influenza 
Participants 
  Gender Race Study Year  
Age BMI Female Male Caucasian 
African 
American 
2013- 
2014 
2014-
2015 
Total 
Participants 
Confirmed Flu 64.31 ± 16.71 32.65 ± 6.71 7 3 5 5 3 7 10 
Matched Controls 62.42 ± 16.02 33.16 ± 9.07 7 3 5 5 3 7 10 
Table 4: Demographics of participants who acquired clinically verified influenza infection and matched controls. Age reported in years ± standard deviation, BMI in kg/m2 ± 
standard deviation. 
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Figure 1: Weight does not impact Influenza HAI antibody generation. HAI for all subjects with flu/flu like illness displayed by 
weight status. HAI shown against vaccine-included strains A/California/H1N1pdm09 (A) and A/Texas/50/H3N2 (B), and major 
circulating strain A/Switzerland/9715293 (C). Comparison between weight and time post vaccination was assessed by ANOVA, p<0.05 
is indicated.  
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 Figure 2: Confirmed Influenza was not predicted by HAI. Hemaglutination Inhibition against A/California/H1N1/pdm09 (A) and 
A/Texas/50/(H3N2) (B) broken down by influenza outcome. Data shown reflects sera from participants with laboratory-confirmed 
influenza infection (Yellow, n=10) with matched controls (black, n=10), and influenza-like-illness excluding confirmed influenza 
(purple, n=54). Statistical values reflect 2-way ANOVA  pwith a statistical cutoff of p=0.05. 
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Figure 3: Confirmed Influenza was not predicted by Microneutralizing Antibodies. Microneutralization against 
A/California/H1N1/pdm09 (A) and A/Texas/50/H3N2 (B). Data shown reflects sera from participants with laboratory clinically influenza 
infection (red, n=10) with matched controls (black, n=10). Both subject groups responded to vaccination (indicated in A, C), but no 
differences or interaction between infected and uninfected were observed. Statistical values reflect 2-way ANOVA with a statistical 
cutoff of p=0.05. 
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Figure 4: Subjects who later became infected had unimpaired HAI against Influenza Vaccine and Circulating Strains.  Subsequent 
Influenza outcome and Hemaglutination inhibition against vaccine-included viruses A/California/H1N1pdm09 (A), vaccine-included 
virus A/Texas/50/H3N2(C), and circulating strain A/H3N2/Switzerland. Statistical values reflect 2-way ANOVA with a cutoff of p=0.05. 
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CHAPTER III: INFLUENZA VACCINATION OF OBESE ADULTS RESULTS IN LESS ACTIVATED CD38+ 
B CELLS BUT UNIMPAIRED ANTIBODY RESPONSE TO INFLUENZA VACCINATION. 
 
Overview 
Background.  
 Obesity is a known risk factor for increased morbidity and mortality from influenza 
infection and, following vaccination, the antibody response is not maintained.  What is not 
known is whether or not obesity impacts the B cell response to vaccination.  
Objective. 
  We tested the hypothesis that obesity would alter the B cell response to vaccination. 
Methods.  
 Obese and healthy weight Caucasian women were recruited and received the 2015-
2016 seasonal influenza inactivated vaccine. Participants provided blood samples pre- and 7 
and 30 days’ post-vaccination. Plasma antibody responses to each vaccine strain were 
measured by hemaglutination inhibition assay.  Vaccine-specific antibody subtypes, IgM, IgG, 
IgG1, IgG2 and IgG3 were assessed by ELISA. Lastly, B cell phenotypes were identified using flow 
cytometry.   
Results.  
 HAI antibody titers and vaccine-specific antibody subclass response did not differ 
between obese and healthy weight subjects. Although B cell phenotypes numbers and 
percentages were not altered by obesity, the expression level of CD38, a marker of activation, 
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was decreased among CD38+ activated B-cells, suggesting incomplete activation of this 
phenotype. 
Conclusions.  
 Obesity was not shown to impair the influenza-specific antibody response at 30 days 
post vaccination, nor the generation of antibody secreting cells at 7 days post vaccination. 
However, decreased expression of the activation marker CD38, may suggest an impairment in 
the ability of B cells to achieve full activation in obese adults. 
 
Introduction 
 Obesity is a growing public concern, affecting 13% of the population worldwide113 and 
34.9% of United States3 in 2014. Between 2011 and 2012, 8.1% of infants and toddlers under 2 
years of age were found to fit age specific definitions for obesity, compared with 16.9% of 
children between 2 and 18 years of age and 34.9% of adults 2. By most estimates, obesity and its 
co-morbidities such as cardiovascular disease, diabetes and dyslipidemia are now a major 
burden on the US Healthcare systems, accounting for 4-7% of US Healthcare expenditure in 
20034, and is estimated to quadruple by 20305. In addition to these well-known co-morbidities 
of obesity, increased susceptibility to infection among obese is also a growing concern. 
Compared with healthy weight individuals, obese humans are at a greater risk for 
hospitalization and death from influenza infection81.  Our lab has previously demonstrated that 
diet-induced obese mice have greater lung inflammation and lung damage and impaired T and 
B cell functions during influenza infection31. In humans, both CD4 and CD8 T cells isolated from 
overweight and obese subjects  show diminished markers of activation and function86. In 
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addition, following influenza vaccination, obese adults generate levels of influenza-specific 
antibodies equivalent to healthy weight individuals at 30 days post vaccination. However, 
increasing BMI is correlated with a greater decrease in antibody levels 1-year post vaccination, 
suggesting that although the B-cells from obese individuals respond appropriately initially, they 
fail to generate or maintain adequate humoral memory84. The drivers of this B-cell dysfunction 
are not currently known, but one possibility is impairments in initial B-cell generation, which is 
the focus of the current investigation. Humoral response to antigen exposure consists of three 
main cell types derived from naïve B-cells: Plasmacells, which can be short or long lived, 
memory B-cells which can respond to future antigen exposures, and plasmablasts which are 
responsible for generating plasma and memory cells.  Plasmablasts and plasma cells are 
generally grouped together as antibody secreting cells (ASCs), as memory B cells do not secrete 
antibody.  The peak of the ASC population occurs 7 days post influenza vaccination114,115. Initial 
functional generation of antibodies followed by impaired antibody maintenance long term 
suggests that obesity may not impact short lived plasma cell generation and function, but may 
impede long lived plasma cell survival or function. Additionally, it is possible that memory B-cell 
function is impaired. Given the previously observed changes in antibody dynamics associated 
with obesity, we sought to characterize the initial B-cell response to influenza vaccination in a 
human population during the 2015-2016 year.  Another possible indicator of altered B-cell 
response is type of immunoglobulin generated: Initial plasma antibodies generated during a 
primary exposure against influenza are Immunoglobulin M (IgM), followed by Immunoglobulin 
G (IgG) and Immunoglobulin G subtypes 1 (IgG1) and 3 (IgG3)116. We were also interested in 
Immunoglobulin G subtype 2 (IgG2) which is not typically elicited against viral antigens, but has 
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been shown to be elevated in HIV infected adults following influenza vaccination117, allowing us 
to consider it a possible marker of immune dysfunction in obesity. 
 
Materials and Methods 
Patient Recruitment 
 Participants were recruited as a part of a prospective observational study carried out at 
the University of North Carolina at Chapel Hill Family Medicine Center, an academic outpatient 
primary care facility in Chapel Hill, North Carolina. Original recruitment criteria for the general 
study included adults 18 years of age and older receiving seasonal Inactivated Influenza Vaccine 
(S-IIV), with exclusion for immunosuppression, immunomodulatory or immunosuppressive 
drugs, acute febrile illness, history of hypersensitivity to any influenza vaccine components, 
history of Guillen-Barre syndrome, use of theophylline preparations, or warfarin. Patients 
recruited to the study provided a blood sample pre vaccination and 28-35 days post 
vaccination. The vaccines administered consisted of a A/California/7/2009(H1N1)pdm09-like 
virus, an A/Switzerland/9715293/2013(H3N2)-like virus, and a B/Phuket/3073/2013-like virus. 
During the 2015-2016 recruitment, 45 previous participants who were Caucasian, female, 
between the ages of 35 and 66, and had a previous weight history of obese or healthy weight 
were asked to provide an additional sample 7 days post vaccination. Forty-four subjects 
completed the study, with one withdrawing due to a scheduling conflict. 
Blood Samples 
Peripheral blood mononuclear cells (PBMCs) and plasma were collected from the same 
blood samples, gathered in heparinized vacuum tubes. PBMCs were isolated using a Ficoll -
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Histopaque gradient and frozen in 10%DMSO/90% Fetal Bovine Serum at -80° C and transferred 
to liquid nitrogen within 24 hours. Plasma was gathered during following initial centrifugation 
of Histopaque separation and immediately stored at -80° C until subsequent analysis. 
Hemaglutination Inhibition Assay (HAI). In order to assess antibody response to specific 
influenza strains included in the vaccine, HAI  was performed in accordance with World Health 
Organization guidelines108. Briefly: Human plasma samples were thawed and incubated with 
Receptor Destroying Enzyme (Denka Seiken, Cambell California) for 18-20 hours at 37C, 
followed by heat inactivation at 56C for 1 hour. Plasma were diluted to 1:10 using sterile 
physiological saline, and used as the start of a serial dilution on a 96-well V-bottom plate. 
Following a 1:2 serial dilution, 4 HAU of virus (either Cal/09/H1N1, Switzerland/H3N2, or 
B/Phuket grown in embryonated chicken eggs) in 25 µL of Phosphate Buffered Solution was 
added to each well. After 15 minutes at room temperature, 50 µL of a 0.5% turkey red blood 
cell solution was added to each well, and hemaglutination inhibition was blindly assessed via 
visual inspection. Reciprocal of HAI is reported. 
ELISA 
 In order to assess antibody class response, an ELISA for influenza vaccine-specific 
immunoglobulins for IgG1, IgG2, IgG3, total IgG, and IgM was performed. Briefly: IgG and IgM 
antibodies were quantified by enzyme-linked immunosorbent assay using the 2015–2016 
seasonal TIV as antigen. Vaccine was diluted and adsorbed to micro titration plates in a 
carbonate coating buffer. After washing, triplicate serum dilutions in PBS were allowed to react 
with antigen, and bound antibodies were detected by a peroxidase-conjugated goat anti-
human IgM, IgG, IgG1, IgG2, and IgG3 (Abcam, Cambridge, MA, USA), followed by a 
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chromogenic substrate. Color intensity was measured by absorbance at 450  nm. Internal 
control plasma were included in each run. Pre- and post-vaccination plasma from each 
participant were tested in the same run. The intra-assay coefficient of variation using this assay 
is 4%. 
Flow Cytometry 
 Frozen PBMCs from a representative subgroup were thawed in a 37 C water bath and 
reconstituted in RPMI complete with 10% Fetal Bovine Serum and Penicillin/Streptomycin 
(Thermo Fisher, Watham Massachusetts). Cells were centrifuged at 350 x g and washed three 
times and 1 x 06 cells were incubated in a 96 well plate at 37 C, 5% CO2 for 2 hours. Cells were 
spun at 350 x g, and treated with Human Fc Block (eBioscience, San Diego California) before 
being stained for viability (Life Technologies, Carlsbad California). Cells were subsequently 
stained for extracellular proteins.  
 Protein targets and fluorophores used included CD19-PE-Alexafluor 610 (Life 
Technologies), CD10-PE (BD Biosciences, San Jose California), IgG-APC (BD Biosciences), IgD-
FITC (BD Biosciences), CD138-Brilliant Violet 605 (Biolegend, San Diego California), CD38-Pacific 
Blue (Exbio, Vestec Czech Republic), and CD27-Brilliant Violet 711 (BD Biosciences).  
After staining, the cells were fixed for no more than 15 minutes using a formaldehyde-based 
fixation buffer (eBioscience) before being centrifuged and reconstituted in PBS + 1% FBS and 
stored at 4 C. Samples were analyzed within 36 hours on a LSR Fortessa at the UNC Flow 
Cytometry Core Facility. Gating and analysis were performed using FlowJo flow cytometry 
software. Samples were run in duplicate. 
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Statistics 
 Data were analyzed using Graphpad Prism. Effects of obesity and vaccination were 
assessed by two-way ANOVA using a statistical cutoff of p<0.05. If an effect was observed, a 
Student’s T-test was employed to determine which timepoints the effect of obesity was 
present. 
 
Results 
Demographics.  
 Subject demographics are included in Table 6. Because subjects were selected based on 
BMI status from 2014 medical records, several subjects who were initially classified as healthy 
weight or obese had weight change that would reclassify them as overweight (4 formerly 
healthy weight, BMI at vaccination=25.3, 25.4, 26.4, 26.4 and two formerly obese, BMI at 
vaccination=28.0, 29.0). No subject from the healthy weight group achieved a higher weight 
than the obese group however, and so the original classifications were used in this analysis. 
Participants classified as Obese had a greater BMI than subjects class ified as Healthy Weight 
(Table 6, BMI p<0.0001).  
Obesity did not affect the immunoglobulin subtypes induced by vaccination.  
 ELISA analysis shows an increase in both healthy weight and obese population’s 
influenza-specific total immunoglobulin G (IgG-total), subtypes 1 (IgG1) and 3(IgG3), and 
immunoglobulin M (IgM) (Figure 5). Influenza specific immunoglobulin 2 (IgG2) did not increase 
in response to influenza vaccination (not shown), and no differences were observed between 
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healthy weight and obese groups. Additionally, there was no correlation found between BMI 
and IgG subtypes.  
HAI titers unaffected by obesity.  
 Strain specific HAI titers did not differ between obese and healthy weight subjects 
before vaccination, seven days post vaccination, or twenty-eight days post vaccination.  As 
shown in Figure 6, vaccination increased the titers for all 3 vaccine strains in both healthy 
weight and obese subjects. In addition, seroconversion (4-fold increase from pre-vaccination 
titer) and seroprotection (HAI > 40) levels did not differ between vaccinated obese and healthy 
weight subjects (data not shown).  
Obesity resulted in decreased CD38 expression on B cells.  
 The gating strategy used for B cell phenotyping is shown in figure 7.  We analyzed two 
plasma cell populations (CD19+ CD38+ CD138+ and CD19+ CD38+ CD138+ CD27+), unswitched 
memory cells (CD19+ CD27+ IgD+ IgG-), switched memory cells (CD19+ CD27+ IgG+ IgD-), 
inactivated memory cells (CD19+ CD27+ CD38-), naïve cells (CD19+ CD27- IgG- IgD+), innate-like 
memory cells (CD19+ CD27- IgG+ IgD-) and activated cells (CD19+ CD38). No differences in 
numbers or percentages of these cells were detected between the obese and healthy weight 
populations (Figure 8). However, mean fluorescent intensity (MFI) for the activation marker, 
CD38, was significantly lower compared with healthy weight in the obese CD19+CD38+ cells  
(Figure 5). 
 
 
 
 
   
52 
Discussion 
This study found lower CD38 expression among CD19+ CD38+ activated B cells  despite 
no differences in B-cell type populations, immunoglobulin types, or vaccine strain specificity 
driven by obesity. It was observed that anti-HA antibodies against all three strains included in 
the vaccine treatment, as well as flu-specific immunoglobulin types G (total, 1, 3) and M 
increased following vaccination, demonstrating that the vaccine elicited a response regardless 
of weight group. Although obese and lean subjects had similar levels of circulating populations 
of B-lymphocytes regardless of weight status or time point post vaccination, obese subjects 
were observed to have lower CD38 intensity among CD38+ cells, suggesting that while obese 
subjects have similar numbers of CD38+ activated B-cells, the extent of activation is reduced. 
These findings were surprising because we would have expected to see shifts in overall B-cell 
population in response to antigen exposure with increases in plasma cells seven days post 
vaccination and an enlarged memory pool thirty days post vaccination, but the dynamics of B-
cell phenotype shifts may have been missed because our study did not assess influenza 
specificity. The influenza specific measures of antibody did respond at each of these timepoints, 
however.  
 CD38’s utility as a marker of activation was initially discovered118 nearly a decade after 
the protein itself was first described in 1980119. CD38 has long been established to be 
upregulated on B-cells, as well as on most other peripheral blood mono- and poly-nuclear cells 
following stimulation with a variety of antigens and mitogens. CD38 has been shown to lower 
the threshold signals necessary to drive B-cell responses in a murine in vitro model120, and CD38 
also been shown to be expressed simultaneously with memory cell formation in mice121. A 
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limitation of this study was that we did not conduct flow cytometry for influenza specificity, so 
we were unable to conclude whether the observed reduction in CD38 from obese subjects ’ 
CD38+ B-cells cells was related specifically to other findings concerning influenza vaccine 
response.  
Another groupl87 and our laboratory have observed defects in B-cell and antibody 
dynamics associated with obesity, but our findings point to different time course and 
phenotypic targets for this observation. Frasca et al found obesity to be associated with a 
decreased numbers of switched memory and transitional B cells and an increased percentage of 
pro-inflammatory late/exhausted memory and naïve B cells in both young and elderly adults. 
We did not share these observations, however the CD38 findings presented herein may support 
this prior work. We attribute this to demographic differences in our respective patient 
populations: Our study was entirely Caucasian females in the state of North Carolina selected 
based on BMI from a previous convenience sample, whereas their recruitment methods were 
unspecified but achieved a racially diverse cohort. Additionally, differences may be explained by 
markers used in flow cytometric definition of memory B-cells. We relied on CD27 as a primary 
marker of B-cell memory, while Frasca et al used CD24 to exclude transitional cells from the B-
cell memory definition. Differing sample storage methods were also relevant, as well as Frasca 
et al’s tightly clustered serological measures: while they found a reduction in antibody response 
at day 7 and 28 post vaccination among their 9 subjects, our findings in the larger but 
demographically dissimilar population (n=22) continue to support our previous findings (n=40)84 
that obesity does not impair initial generation of influenza specific antibodies.  
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The decreased MFI of CD38 observed in obese populations suggests that CD19+ CD38+ 
“activated B cells” are overall less active in obese populations and this may therefore contribute 
to the long-term decline of memory cells, resulting in the previously reported84 drop in 
antibody titer. Further work examining additional time points and additional markers of B cell 
activation is needed to better understand the long-term loss of antibody protection in obese 
populations.  
In summary, this study provides clear evidence that there are no differences in vaccine-
induced immunoglobulin subtypes or strain-specific flue protection between average weight and 
obese populations. There is however a drop in CD38+ MFI in obese patients, which suggested 
impaired B-cell activation. Future work in murine models of obesity will be critical in determining 
the mechanisms behind the CD38 MFI and how it translates long-term to a drop in memory B 
cells, and the overall loss of protection from influenza in obesity.   
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Table 6: 
Participant 
Demographics  n 
BMI 
Range 
Average 
BMI 
Average 
Age 
Non-
Diabetic 
Pre-
Diabetic 
Type 2 
Diabetic 
Healthy 
Weight 22 
18.85-
26.37 
22.4 ± 
2.3 
53.05 ± 
10.3 22 (100%) 0 0 
Obese 22 
28.03-
45.28 
34.8 ± 
4.6 
54.77 ± 
8.1 18 (82%) 2 (9%) 2 (9%) 
Table 6: Demographic data of subjects. All subjects were female, non-Hispanic Caucasian. 
Average BMI and Age are reported ± standard deviation.  
 
 
 
 
Table 7: Flow 
Cytometry 
Subset 
Demographics  
n BMI Range 
Average 
BMI 
Average 
Age 
Non-
Diabetic 
Pre-
Diabetic 
Type 2 
Diabetic 
Healthy 
Weight 8 
18.85-
24.37 
22.11 ± 
1.96 
55.11 ± 
10.76 
8 
(100%) 0 0 
Obese 8 29.00-37.92 
33.01 ± 
3.21 
51.38 ± 
8.42 
7 
(87.5%) 
1 
(12.5%) 0 
Table 7: Demographic data of subjects included in flow cytometric analysis. All subjects were female, 
non-Hispanic Caucasian. Average BMI and Age are reported ± standard deviation. 
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Figure 5: Influenza Vaccination Induced Antibodies by Class: IgM (A),  IgG-total (B), IgG1 (C), 
and IgG3 (E) but not in IgG2 (D). Statistics reported by ANOVA with a statistical cutoff of p=0.05.  
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Figure 6: Strain specific HAI response. 
Bars represent average +/- SEM. 
Vaccination drove an increase in all three 
strains. Reported p-values reflect ANOVA 
with a statistical cutoff of p=0.05. 
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Figure 7: Representative Gating for Flow Cytometry Data. Arrows demonstrate which events were 
subsequently analyzed in the next gate. Only live cells as defined by the top row were considered. Multiple 
arrows from the same panel, as in the CD27 panel, means that the subsequent gate was applied 
equivalently to both the positive and negative populations and are considered separately. Positioning of 
gates was based on Fluorescent-Minus-One for that target. 
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Figure 8: B-cell Subtype population sizes as a percentage of CD19+ B-cells. Neither obesity nor 
vaccination significantly altered any of these populations. (ANOVA, p<.05)  
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Figure 9: Mean Fluorescence Intensity of CD38 among CD38+B-cells. Reported p values reflect Student’s 
T-test (Day 0: p=0.0368, Day 7 p=0.0438, thirty days p=0.0614) conducted post-hoc to ANOVA (Obesity 
p=0.0368). A statistical cutoff for significance of p<0.05 was used. 
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CHAPTER IV: SYNTHESIS 
Overview of research findings 
 This doctoral dissertation investigated two main questions about influenza vaccination 
in obese humans. Firstly, does vaccination mitigate the disparity in influenza outcomes among 
obese humans? And secondly, are there phenotypic differences in humoral response to 
vaccination among obese humans that may explain influenza vaccine response differences? In 
these investigations, we observed that obese humans were more susceptible to influenza-like-
illness regardless of humoral response to vaccination through two separate measures. We did 
not observe phenotypic differences in B-cell response, both cellular and serological.   
 
Do differences in antibody response to vaccine explain why some vaccinated individuals still 
get influenza? 
The hemaglutination inhibition assay (HAI) is a quantitative method which assesses the 
ability of anti-influenza antibody’s inhibition of the virus’ inherent hemagluttinating ability, that 
is: ability to link red blood cells’ sialic acid residues and form a lattice structure. It is commonly 
used as a correlate of protection and assessment of response to vaccination. However, our 
study and others122 have remarked upon its’ shortcomings as a correlate of protection against 
influenza. There have been suggestions in the literature that microneutralization may serve as a 
better correlate of protection. Rather than relying on antibody’s ability to block solely 
hemaglutination, microneutralization measures antibody’s ability to block viral replication in 
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live cells. While blocking a virus’s ability to attach to sialic acid residues should prohibit viral 
replication, blocking other viral epitopes can also inhibit viral replication123. Microneutralization 
is therefore a more sensitive and biologically relevant assay and may be more useful for 
measuring susceptibility to influenza infection. For example, binding the stalk-region of 
hemagglutinin instead of the head region will inhibit merging of the viral and vesicular 
membranes, trapping endocytosed viruses inside vesicles fated for degradation. 
Neuraminidase-inhibiting antibodies can impair neuraminidase’ role in both viral exit124 and 
possibly viral entry125, but our findings concluded that microneutralization titer was unimpaired 
in vaccinated subjects who were infected with influenza, demonstrating that a successful 
generation of microneutralizing antibodies 30 days post vaccination does not offer protection 
to obese subjects. In summary, neither HAI nor microneutralization at 30 days post vaccination 
offered protections against subsequent influenza infection. 
 
Does obesity drive different B-cell phenotypic outcomes? 
 To answer this question, we used flow cytometry to measure B-cell population 
phenotypes, and ELISA and HAI to assess antibody phenotypes. Given the role of B-cells in 
generation of humoral immunity and obese subjects’ demonstrated impairments in long -term 
humoral maintenance. We expected that a defect during initial B-cell response to vaccination 
might explain long-term effects, however this investigation did not identify any differences in B-
cell population numbers. Importantly, the marker of activation CD38 was more highly 
expressed among CD19+ CD38+ B-cells from healthy weight subjects, suggesting that there may 
be impairments in B-cell activation among obese Caucasian women. CD38 is a multifunction 
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protein which is associated with activation on lymphocytes, and has also been found to dictate 
age-related decline in Nicotinamide Adenine Dinucleotide (NAD) and contribute to 
mitochondrial dysfunction related to aging in mice126, which could suggest that B-cell 
impairments in metabolism may be worth investigation. CD38 is expressed on a variety of cells, 
and global expression of CD38 has also been implicated as necessary for induction of diet-
induced obesity in mice127. However, our findings suggest paradoxical reduction in CD38 
expression on obese B-cells, or perhaps that CD38 expression on B-cells is not involved in diet 
induced obesity. 
In addition to an absence of B-cell population shifts, obesity did not drive differences in 
immunoglobulin class or subclass generation for influenza specific IgM, IgG, IgG1, IgG2, or IgG3 
in the population, nor differences in strain-specific HAI. This differed from our preliminary 
findings presented at the Federation of American Societies for Experimental Biology128 where 
young (18-35) obese participants had impaired IgG1 response compared to healthy weight, 
however the reduced sample size, differing age, and race selection in this follow-up suggests 
our original findings may still be valid in younger populations. 
A recently published article did demonstrate defects in memory cell generation87 which 
were also not observed in the studies reported here, likely due to differences in population, 
methods, and cell population definitions.   
 
Recommendations for future research 
There are two key outcomes from this dissertation which should be addressed in future studies: 
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1) Greater incidence of laboratory confirmed and influenza-like illness among obese 
vaccinated adults. 
2) Lack of antibody or B-cell differences in obese subjects 30 days post vaccination. 
In addressing greater incidence of influenza-like illness, a larger observational study will 
be necessary to refine this finding from influenza-like illness to clinically confirmed influenza 
cases. Continuing the subject recruitment our laboratory has been conducting over the last few 
years will provide more data on this phenomenon, however year-to-year variances in influenza 
may make conclusions elusive. Viable solutions include expanding the observational pool of 
participants from the previous five-hundred to one-thousand, and performing nasal-swabs to 
confirm cases of influenza for every subject who reports flu-like symptoms. In doing so, many 
subjects described as flu-like illness, or even mild-flu symptoms, may be redefined as clinically 
confirmed in future years.  
In addressing lack of antibody or B-cell alterations driven by obesity, I suggest two 
future directions that may assess obese individuals’ increased risk for influenza infection. Long -
term maintenance of circulating antibody is provided by long-lived plasma cells within the bone 
marrow, wherein microenvironment is altered by obesity129. Given the challenges associated 
with human studies in general, a murine study of B-cell trafficking and bone-marrow 
microenvironment may be optimal for addressing this question. Our lab has demonstrated that 
diet-induced obese mice, similar to humans, can mount an adequate antibody response at 30 
days post influenza infection, but that these antibodies are lost 3 months later57. Using this 
model, the bone marrow can be examined to determine if plasma cells fail to be maintained in 
the obese bone marrow environment. And finally, further characterizing dynamics of humoral 
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response to vaccination in obesity may be warranted: although obese subjects had similar 
levels of influenza-specific antibodies 7 and 30 days post vaccination, and subsequently infected 
subjects had similar humoral response to uninfected controls 30 days post vaccination, we do 
not have a clear picture of circulating antibody level at time of exposure to influenza. Examining 
this would require regular follow up with patients to gather serum at time points throughout 
the influenza season, but may also be able to identify subjects with sub-clinical illness and 
exposure events to serve as controls.  
Future investigations could focus on verifying that infected individuals do not lose 
protective level of antibodies. Determining mechanisms of long-term deficiency and dynamics 
of influenza susceptibility would present an enormous public health opportunity: the possibility 
to prevent influenza infection with multiple doses of the seasonal influenza vaccination within 
at-risk populations. If antibodies are present at time of exposure, such a study may also suggest 
that this vaccination strategy would be ineffective at preventing illness, and further suggest 
that B-cell characteristics are less important to assessing influenza protection than other 
immune cells. It may therefore be necessary to prioritize T-cell phenotypic analysis as a better 
correlate or protection following vaccination. 
T-cells are central to the acquired immune response, and have many interactions with 
innate immunity as well. T-cells form germinal centers with B-cells, provide signals to 
Macrophage130 and Natural Killer Cells131, and receive signals from dendritic cells132.  CD8 T-cells 
also destroy viral infected cells. While assessing T-cells may be more technically challenging and 
expensive than assessing antibodies, measures based on their activity should nonetheless be 
considered candidates as correlates of protection following influenza vaccination. 
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In closing: influenza is a virus with a significant public health burden causing 
approximately 100,000 deaths annually133. Previous work has demonstrated that obesity is a 
risk factor for complications from influenza, but why these complications arise is not well 
understood134. This dissertation has begun to answer this question by delving into the 
subtleties and efficacy of humoral response in healthy weight vs obese individuals. Our current 
findings support the conclusion that initial humoral response shows slight differences between 
healthy weight and obese individuals, though overall humoral response is initially unchanged. 
Further work on this question should delve deeply into other time points to examine B cell 
memory response, as well as other aspects of the immune system through study of T cell 
response. These future studies will develop a more complete understanding of the impact of 
obesity on the immune system’s response to infections, and critically, influenza.
 
   
67 
REFERENCES 
1 Kroger, A. T. et al. General recommendations on immunization: recommendations of 
the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55, 1-
48 (2006). 
2 Flegal, K. M., Carroll, M. D., Kit, B. K. & Ogden, C. L. PRevalence of obesity and trends in 
the distribution of body mass index among us adults, 1999-2010. JAMA 307, 491-497, 
doi:10.1001/jama.2012.39 (2012). 
3 Ogden, C. L., Carroll, M. D., Kit, B. K. & Flegal, K. M. PRevalence of childhood and adult 
obesity in the united states, 2011-2012. JAMA 311, 806-814, 
doi:10.1001/jama.2014.732 (2014). 
4 Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L. & Brown, M. Health and 
economic burden of the projected obesity trends in the USA and the UK. Lancet 378, 
815-825, doi:10.1016/S0140-6736(11)60814-3 (2011). 
5 Wang, Y., Beydoun, M. A., Liang, L., Caballero, B. & Kumanyika, S. K. Will all Americans 
become overweight or obese? estimating the progression and cost of the US obesity 
epidemic. Obesity (Silver Spring) 16, 2323-2330, doi:10.1038/oby.2008.351 (2008). 
6 Keys, A. Obesity and heart disease. J Chronic Dis 1, 458-461 (1955). 
7 Duncan, G. G., Shumway, N. P., Williams, T. L. & Fetter, F. THE CLINICAL APPLICATION OF 
DUODENAL EXTRACT (MACALLUM-LAUGHTON) IN DIABETES MELLITUS. The American 
Journal of the Medical Sciences 189, 403-418 (1935). 
8 Masini, V., Rulli, V. & Concina, B. [Dyslipidemia factors in arterioscelerotic heart 
disease]. Cuore Circ 44, 185-204 (1960). 
9 Ross, R. Atherosclerosis--an inflammatory disease. N Engl J Med 340, 115-126, 
doi:10.1056/NEJM199901143400207 (1999). 
10 Losser, M. R., Bernard, C., Beaudeux, J. L., Pison, C. & Payen, D. Glucose modulates 
hemodynamic, metabolic, and inflammatory responses to lipopolysaccharide in rabbits. 
J Appl Physiol (1985) 83, 1566-1574 (1997). 
11 Brooks, P. M. The burden of musculoskeletal disease--a global perspective. Clin 
Rheumatol 25, 778-781, doi:10.1007/s10067-006-0240-3 (2006). 
12 Shiffman, M. L., Sugerman, H. J., Kellum, J. H., Brewer, W. H. & Moore, E. W. Gallstones 
in patients with morbid obesity. Relationship to body weight, weight loss and 
gallbladder bile cholesterol solubility. Int J Obes Relat Metab Disord 17, 153-158 (1993). 
 
   
68 
13 Moller, H., Mellemgaard, A., Lindvig, K. & Olsen, J. H. Obesity and cancer risk: a Danish 
record-linkage study. Eur J Cancer 30A, 344-350 (1994). 
14 Finkelstein, E. A., Fiebelkorn, I. C. & Wang, G. National medical spending attributable to 
overweight and obesity: how much, and who's paying? Health Aff (Millwood) Suppl Web 
Exclusives, W3-219-226 (2003). 
15 Thompson, M. et al. Estimates of deaths associated with seasonal influenza-United 
States, 1976-2007. Morbidity and Mortality Weekly Report 59, 1057-1062 (2010). 
16 Morgan, O. W. et al. Morbid obesity as a risk factor for hospitalization and death due to 
2009 pandemic influenza A (H1N1) disease. PloS one 5, e9694 (2010). 
17 Baxter, R., Ray, G. T. & Fireman, B. H. Effect of influenza vaccination on hospitalizations 
in persons aged 50 years and older. Vaccine 28, 7267-7272 (2010). 
18 Molinari, N. A. et al. The annual impact of seasonal influenza in the US: measuring 
disease burden and costs. Vaccine 25, 5086-5096, doi:10.1016/j.vaccine.2007.03.046 
(2007). 
19 Audsley, J. M. & Tannock, G. A. Cell-based influenza vaccines: progress to date. Drugs 
68, 1483-1491 (2008). 
20 Maassab, H. F. & Bryant, M. L. The development of live attenuated cold-adapted 
influenza virus vaccine for humans. Rev Med Virol 9, 237-244 (1999). 
21 Hoft, D. F. et al. Live and inactivated influenza vaccines induce similar humoral 
responses, but only live vaccines induce diverse T-cell responses in young children. J 
Infect Dis 204, 845-853, doi:10.1093/infdis/jir436 (2011). 
22 Ambrose, C. S., Wu, X. & Belshe, R. B. The efficacy of live attenuated and inactivated 
influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 
29, 806-811, doi:10.1097/INF.0b013e3181e2872f (2010). 
23 Parker, D. C. T cell-dependent B cell activation. Annual review of immunology 11, 331-
360, doi:10.1146/annurev.iy.11.040193.001555 (1993). 
24 Chen, K. et al. Immunoglobulin D enhances immune surveillance by activating 
antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nature 
immunology 10, 889-898, doi:10.1038/ni.1748 (2009). 
25 Sarma, J. V. & Ward, P. A. The complement system. Cell Tissue Res 343, 227-235, 
doi:10.1007/s00441-010-1034-0 (2011). 
 
   
69 
26 Kawano, Y., Noma, T., Kou, K., Yoshizawa, I. & Yata, J. Regulation of human IgG subclass 
production by cytokines: human IgG subclass production enhanced differentially by 
interleukin-6. Immunology 84, 278-284 (1995). 
27 Frasca, D. et al. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated 
during the 2011-2012 influenza vaccine season. Immun Ageing 10, 14, 
doi:10.1186/1742-4933-10-14 (2013). 
28 Cerutti, A. The regulation of IgA class switching. Nat Rev Immunol 8, 421-434, 
doi:10.1038/nri2322 (2008). 
29 Sarvetnick, N., Liggitt, D., Pitts, S. L., Hansen, S. E. & Stewart, T. A. Insulin-dependent 
diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and 
interferon-gamma. Cell 52, 773-782 (1988). 
30 Johnson, A. R., Milner, J. J. & Makowski, L. The inflammation highway: metabolism 
accelerates inflammatory traffic in obesity. Immunol Rev 249, 218-238, 
doi:10.1111/j.1600-065X.2012.01151.x (2012). 
31 Milner, J. J. et al. Obesity Increases Mortality and Modulates the Lung Metabolome 
during Pandemic H1N1 Influenza Virus Infection in Mice. J Immunol 194, 4846-4859, 
doi:10.4049/jimmunol.1402295 (2015). 
32 Travers, R. L., Motta, A. C., Betts, J. A., Bouloumie, A. & Thompson, D. The impact of 
adiposity on adipose tissue-resident lymphocyte activation in humans. Int J Obes (Lond) 
39, 762-769, doi:10.1038/ijo.2014.195 (2015). 
33 Conde, J. et al. An update on leptin as immunomodulator. Expert review of clinical 
immunology 10, 1165-1170, doi:10.1586/1744666x.2014.942289 (2014). 
34 Considine, R. V. et al. Serum immunoreactive-leptin concentrations in normal-weight 
and obese humans. N Engl J Med 334, 292-295, doi:10.1056/nejm199602013340503 
(1996). 
35 Gerriets, V. A. & MacIver, N. J. Role of T cells in malnutrition and obesity. Front Immunol 
5, 379, doi:10.3389/fimmu.2014.00379 (2014). 
36 Lam, Q. L., Wang, S., Ko, O. K., Kincade, P. W. & Lu, L. Leptin signaling maintains B-cell 
homeostasis via induction of Bcl-2 and Cyclin D1. Proc Natl Acad Sci U S A 107, 13812-
13817, doi:10.1073/pnas.1004185107 (2010). 
37 Ramirez, O. & Garza, K. M. Leptin deficiency in vivo enhances the ability of splenic 
dendritic cells to activate T cells. Int Immunol 26, 627-636, doi:10.1093/intimm/dxu067 
(2014). 
 
   
70 
38 Lamas, B. et al. Leptin modulates dose-dependently the metabolic and cytolytic 
activities of NK-92 cells. J Cell Physiol 228, 1202-1209, doi:10.1002/jcp.24273 (2013). 
39 Yang, R. & Barouch, L. A. Leptin signaling and obesity: cardiovascular consequences. Circ 
Res 101, 545-559, doi:10.1161/CIRCRESAHA.107.156596 (2007). 
40 Allison, M. B. & Myers, M. G., Jr. 20 years of leptin: connecting leptin signaling to 
biological function. J Endocrinol 223, T25-35, doi:10.1530/JOE-14-0404 (2014). 
41 Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev 
Immunol 12, 325-338, doi:10.1038/nri3198 (2012). 
42 Nahrendorf, M. & Swirski, F. K. Lifestyle effects on hematopoiesis and atherosclerosis. 
Circ Res 116, 884-894, doi:10.1161/CIRCRESAHA.116.303550 (2015). 
43 Matarese, G. et al. Leptin increase in multiple sclerosis associates with reduced number 
of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A 102, 5150-5155, 
doi:10.1073/pnas.0408995102 (2005). 
44 Bruno, A., Conus, S., Schmid, I. & Simon, H. U. Apoptotic pathways are inhibited by 
leptin receptor activation in neutrophils. J Immunol 174, 8090-8096 (2005). 
45 O'Rourke, L., Yeaman, S. J. & Shepherd, P. R. Insulin and leptin acutely regulate 
cholesterol ester metabolism in macrophages by novel signaling pathways. Diabetes 50, 
955-961 (2001). 
46 Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance 
associated with both lipoatrophy and obesity. Nature medicine 7, 941-946, 
doi:10.1038/90984 (2001). 
47 Pang, T. T. & Narendran, P. The distribution of adiponectin receptors on human 
peripheral blood mononuclear cells. Ann N Y Acad Sci 1150, 143-145, 
doi:10.1196/annals.1447.021 (2008). 
48 Wilk, S. et al. Adiponectin is a negative regulator of antigen-activated T cells. Eur J 
Immunol 41, 2323-2332, doi:10.1002/eji.201041349 (2011). 
49 Kugelberg, E. T cell responses: B cells control T cell traffic. Nat Rev Immunol 15, 332-333, 
doi:10.1038/nri3860 (2015). 
50 Neumeier, M. et al. Different effects of adiponectin isoforms in human monocytic cells. J 
Leukoc Biol 79, 803-808, doi:10.1189/jlb.0905521 (2006). 
51 Bertola, A. et al. Identification of adipose tissue dendritic cells correlated with obesity-
associated insulin-resistance and inducing Th17 responses in mice and patients. 
Diabetes 61, 2238-2247, doi:10.2337/db11-1274 (2012). 
 
   
71 
52 Christiansen, T., Richelsen, B. & Bruun, J. M. Monocyte chemoattractant protein-1 is 
produced in isolated adipocytes, associated with adiposity and reduced after weight loss 
in morbid obese subjects. Int J Obes (Lond) 29, 146-150, doi:10.1038/sj.ijo.0802839 
(2005). 
53 Bozaoglu, K. et al. Chemerin is associated with metabolic syndrome phenotypes in a 
Mexican-American population. J Clin Endocrinol Metab 94, 3085-3088, 
doi:10.1210/jc.2008-1833 (2009). 
54 Cottam, D. R. et al. The chronic inflammatory hypothesis for the morbidity associated 
with morbid obesity: implications and effects of weight loss. Obes Surg 14, 589-600, 
doi:10.1381/096089204323093345 (2004). 
55 Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose 
tissue. J Clin Invest 112, 1796-1808, doi:10.1172/jci19246 (2003). 
56 Yeang, C. H., McCormick, F. & Levine, A. Combinatorial patterns of somatic gene 
mutations in cancer. Faseb j 22, 2605-2622, doi:10.1096/fj.08-108985 (2008). 
57 Milner, J. J. et al. Diet-induced obese mice exhibit altered heterologous immunity during 
a secondary 2009 pandemic H1N1 infection. J Immunol 191, 2474-2485, 
doi:10.4049/jimmunol.1202429 (2013). 
58 LaMere, M. W. et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity 
against influenza virus. J Immunol 186, 4331-4339, doi:10.4049/jimmunol.1003057 
(2011). 
59 Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in 
adipose tissue macrophage polarization. J Clin Invest 117, 175-184, 
doi:10.1172/JCI29881 (2007). 
60 Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. 
Nat Rev Immunol 8, 958-969, doi:10.1038/nri2448 (2008). 
61 Weisberg, S. P. et al. CCR2 modulates inflammatory and metabolic effects of high-fat 
feeding. J Clin Invest 116, 115-124, doi:10.1172/JCI24335 (2006). 
62 Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time 
for reassessment. F1000Prime Rep 6, 13, doi:10.12703/P6-13 (2014). 
63 Tzanavari, T., Giannogonas, P. & Karalis, K. P. TNF-alpha and obesity. Curr Dir 
Autoimmun 11, 145-156, doi:10.1159/000289203 (2010). 
64 Eder, K., Baffy, N., Falus, A. & Fulop, A. K. The major inflammatory mediator interleukin-
6 and obesity. Inflamm Res 58, 727-736, doi:10.1007/s00011-009-0060-4 (2009). 
 
   
72 
65 Nijhuis, J. et al. Neutrophil activation in morbid obesity, chronic activation of acute 
inflammation. Obesity (Silver Spring) 17, 2014-2018, doi:10.1038/oby.2009.113 (2009). 
66 Xu, X. et al. Obesity is associated with more activated neutrophils in African American 
male youth. Int J Obes (Lond) 39, 26-32, doi:10.1038/ijo.2014.194 (2015). 
67 Wang, J. & Shi, G. P. Mast cell stabilization: novel medication for obesity and diabetes. 
Diabetes Metab Res Rev 27, 919-924, doi:10.1002/dmrr.1272 (2011). 
68 Talukdar, S. et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet 
through secreted elastase. Nature medicine 18, 1407-1412, doi:10.1038/nm.2885 
(2012). 
69 Ng, M. F. The role of mast cells in wound healing. Int Wound J 7, 55-61, 
doi:10.1111/j.1742-481X.2009.00651.x (2010). 
70 Palmer, C. S., Ostrowski, M., Balderson, B., Christian, N. & Crowe, S. M. Glucose 
metabolism regulates T cell activation, differentiation, and functions. Front Immunol 6, 
1, doi:10.3389/fimmu.2015.00001 (2015). 
71 Michalek, R. D. et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic 
programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 186, 
3299-3303, doi:10.4049/jimmunol.1003613 (2011). 
72 Stentz, F. B. & Kitabchi, A. E. Activated T lymphocytes in Type 2 diabetes: implications 
from in vitro studies. Curr Drug Targets 4, 493-503 (2003). 
73 Denkers, E. Y. & Gazzinelli, R. T. Regulation and function of T-cell-mediated immunity 
during Toxoplasma gondii infection. Clin Microbiol Rev 11, 569-588 (1998). 
74 Shaikh, S. R., Haas, K. M., Beck, M. A. & Teague, H. The effects of diet-induced obesity on 
B cell function. Clin Exp Immunol 179, 90-99, doi:10.1111/cei.12444 (2015). 
75 Winer, D. A. et al. B cells promote insulin resistance through modulation of T cells and 
production of pathogenic IgG antibodies. Nature medicine 17, 610-617, 
doi:10.1038/nm.2353 (2011). 
76 Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with 
induced pluripotent stem cell and heart-on-chip technologies. Nature medicine 20, 616-
623, doi:10.1038/nm.3545 (2014). 
77 Younossi, Z. M. et al. Gene expression profile associated with superimposed non-
alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver 
Int 29, 1403-1412, doi:10.1111/j.1478-3231.2009.02060.x (2009). 
 
   
73 
78 Shah, K., Alio, A. P., Hall, W. J. & Luque, A. E. The physiological effects of obesity in HIV-
infected patients. Journal of AIDS & Clinical Research 2012 (2012). 
79 Villarroya, F., Domingo, P. & Giralt, M. Lipodystrophy associated with highly active anti -
retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced 
mitochondrial toxicity. Trends Pharmacol Sci 26, 88-93, doi:10.1016/j.tips.2004.12.005 
(2005). 
80 Guaraldi, G. et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical 
atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 208, 
222-227 (2010). 
81 Jain, S. & Chaves, S. S. Obesity and influenza. Clin Infect Dis 53, 422-424, 
doi:10.1093/cid/cir448 (2011). 
82 Sampson, M. G. & Grassino, A. E. Load compensation in obese patients during quiet tidal 
breathing. J Appl Physiol Respir Environ Exerc Physiol 55, 1269-1276 (1983). 
83 Milner, J. J. & Beck, M. A. The impact of obesity on the immune response to infection. 
Proc Nutr Soc 71, 298-306, doi:10.1017/S0029665112000158 (2012). 
84 Sheridan, P. A. et al. Obesity is associated with impaired immune response to influenza 
vaccination in humans. Int J Obes (Lond) 36, 1072-1077, doi:10.1038/ijo.2011.208 
(2012). 
85 Karlsson, E. A., Sheridan, P. A. & Beck, M. A. Diet-induced obesity impairs the T cell 
memory response to influenza virus infection. J Immunol 184, 3127-3133, 
doi:10.4049/jimmunol.0903220 (2010). 
86 Paich, H. A. et al. Overweight and obese adult humans have a defective cellular immune 
response to pandemic H1N1 influenza A virus. Obesity (Silver Spring, Md.) 21, 2377-
2386, doi:10.1002/oby.20383 (2013). 
87 Frasca, D. et al. Obesity decreases B cell responses in young and elderly individuals. 
Obesity (Silver Spring) 24, 615-625, doi:10.1002/oby.21383 (2016). 
88 Izurieta , H. S. et al. Influenza and the Rates of Hospitalization for Respiratory Disease 
among Infants and Young Children. New England Journal of Medicine 342, 232-239, 
doi:doi:10.1056/NEJM200001273420402 (2000). 
89 Garrastazu, R. et al. Prevalence of Influenza Vaccination in Chronic Obstructive 
Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. Arch 
Bronconeumol 52, 88-95, doi:10.1016/j.arbres.2015.09.001 (2016). 
 
   
74 
90 Sandoval, C. et al. Risk of hospitalization during influenza season among a cohort of 
patients with congestive heart failure. Epidemiol Infect 135, 574-582, 
doi:10.1017/S095026880600714X (2007). 
91 Neuzil, K. M., Reed, G. W., Mitchel, E. F., Simonsen, L. & Griffin, M. R. Impact of 
influenza on acute cardiopulmonary hospitalizations in pregnant women. American 
journal of epidemiology 148, 1094-1102 (1998). 
92 Coleman, L. A. et al. Evaluation of obesity as an independent risk factor for medically 
attended laboratory-confirmed influenza. Influenza and other respiratory viruses 7, 160-
167, doi:10.1111/j.1750-2659.2012.00377.x (2013). 
93 Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D. & Ogden, C. L. TRends in 
obesity among adults in the united states, 2005 to 2014. JAMA 315, 2284-2291, 
doi:10.1001/jama.2016.6458 (2016). 
94 Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in 
children and adults during 1980-2013: a systematic analysis for the Global Burden of 
Disease Study 2013. Lancet 384, 766-781, doi:10.1016/S0140-6736(14)60460-8 (2014). 
95 Jagadesh, A., Salam, A. A., Mudgal, P. P. & Arunkumar, G. Influenza virus neuraminidase 
(NA): a target for antivirals and vaccines. Arch Virol, doi:10.1007/s00705-016-2907-7 
(2016). 
96 Kong, W. et al. Novel reassortant influenza viruses between pandemic (H1N1) 2009 and 
other influenza viruses pose a risk to public health. Microbial pathogenesis 89, 62-72, 
doi:10.1016/j.micpath.2015.09.002 (2015). 
97 Xie, H. et al. H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and 
Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps. 
Sci Rep 5, 15279, doi:10.1038/srep15279 (2015). 
98 Ohmit, S. E. et al. Influenza vaccine effectiveness in the 2011-2012 season: protection 
against each circulating virus and the effect of prior vaccination on estimates. Clin Infect 
Dis 58, 319-327, doi:10.1093/cid/cit736 (2014). 
99 Kroon, F. P. et al. Restored humoral immune response to influenza vaccination in HIV‐
infected adults treated with highly active antiretroviral therapy. Aids 12, F217-F223 
(1998). 
100 Mandelboim, M. et al. Significant cross reactive antibodies to influenza virus in adults 
and children during a period of marked antigenic drift. BMC infectious diseases 14, 346, 
doi:10.1186/1471-2334-14-346 (2014). 
 
   
75 
101 Miller, M. S. et al. 1976 and 2009 H1N1 influenza virus vaccines boost anti-
hemagglutinin stalk antibodies in humans. J Infect Dis 207, 98-105, 
doi:10.1093/infdis/jis652 (2013). 
102 Ohmit, S. E., Petrie, J. G., Cross, R. T., Johnson, E. & Monto, A. S. Influenza 
hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. 
J Infect Dis 204, 1879-1885, doi:10.1093/infdis/jir661 (2011). 
103 Wang, L. et al. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza 
Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II 
Randomized Trial. J Pediatric Infect Dis Soc 5, 170-179, doi:10.1093/jpids/piv041 (2016). 
104 McElhaney, J. E. Influenza vaccine responses in older adults. Ageing Res Rev 10, 379-
388, doi:10.1016/j.arr.2010.10.008 (2011). 
105 Beyer, W. E., Palache, A. M., Luchters, G., Nauta, J. & Osterhaus, A. D. Seroprotection 
rate, mean fold increase, seroconversion rate: which parameter adequately expresses 
seroresponse to influenza vaccination? Virus research 103, 125-132, 
doi:10.1016/j.virusres.2004.02.024 (2004). 
106 Goodwin, K., Viboud, C. & Simonsen, L. Antibody response to influenza vaccination in 
the elderly: A quantitative review. Vaccine 24, 1159-1169, 
doi:http://dx.doi.org/10.1016/j.vaccine.2005.08.105 (2006). 
107 Carlson, C. M. et al. Transforming growth factor-β: activation by neuraminidase and role 
in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog 6, e1001136 (2010). 
108 WHO manual on animal influenza diagnosis and surveillance. Geneva: World Health 
Organization (2002). 
109 Karlsson, E. A. et al. Visualizing real-time influenza virus infection, transmission and 
protection in ferrets. Nat Commun 6, 6378, doi:10.1038/ncomms7378 (2015). 
110 DiazGranados, C. A. et al. Efficacy of high-dose versus standard-dose influenza vaccine in 
older adults. N Engl J Med 371, 635-645, doi:10.1056/NEJMoa1315727 (2014). 
111 Ko, E. J. et al. MF59 adjuvant effects on inducing isotype-switched IgG antibodies and 
protection after immunization with T-dependent influenza virus vaccine in the absence 
of CD4+ T cells. J Virol, doi:10.1128/JVI.00339-16 (2016). 
112 Memoli, M. J. et al. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies 
as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge 
Model. MBio 7, doi:10.1128/mBio.00417-16 (2016). 
113 Cole, T. J., Bellizzi, M. C., Flegal, K. M. & Dietz, W. H. Establishing a standard definition 
for child overweight and obesity worldwide: international survey. Bmj 320, 1240 (2000). 
 
   
76 
114 Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived 
plasma cell. Nat Rev Immunol 6, 741-750, doi:10.1038/nri1886 (2006). 
115 Malaspina, A. et al. Compromised B cell responses to influenza vaccination in HIV-
infected individuals. J Infect Dis 191, 1442-1450, doi:10.1086/429298 (2005). 
116 Westra, J. et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses 
after influenza vaccination in rheumatoid arthritis patients. Clinical and Experimental 
Immunology 178, 40-47, doi:10.1111/cei.12390 (2014). 
117 Crum‐Cianflone, N. et al. Immunoglobulin G subclass levels and antibody responses to 
the 2009 influenza A (H1N1) monovalent vaccine among human immunodeficiency virus 
(HIV)‐infected and HIV‐uninfected adults. Clinical & Experimental Immunology 168, 135-
141 (2012). 
118 Jackson, D. G. & Bell, J. I. Isolation of a cDNA encoding the human CD38 (T10) molecule, 
a cell surface glycoprotein with an unusual discontinuous pattern of expression during 
lymphocyte differentiation. J Immunol 144, 2811-2815 (1990). 
119 Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H. & Schlossman, S. F. Discrete stages 
of human intrathymic differentiation: analysis of normal thymocytes and leukemic 
lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A 77, 1588-1592 (1980). 
120 Lund, F. E., Yu, N., Kim, K. M., Reth, M. & Howard, M. C. Signaling through CD38 
augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. J 
Immunol 157, 1455-1467 (1996). 
121 Ridderstad, A. & Tarlinton, D. M. Kinetics of establishing the memory B cell population 
as revealed by CD38 expression. J Immunol 160, 4688-4695 (1998). 
122 Dunning, A. J. et al. Correlates of Protection against Influenza in the Elderly: Results 
from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol 23, 228-235, 
doi:10.1128/CVI.00604-15 (2016). 
123 Doyle, T. M. et al. The universal epitope of influenza A viral neuraminidase 
fundamentally contributes to enzyme activity and viral replication. J Biol Chem 288, 
18283-18289, doi:10.1074/jbc.M113.468884 (2013). 
124 Air, G. M. & Laver, W. G. The neuraminidase of influenza virus. Proteins 6, 341-356, 
doi:10.1002/prot.340060402 (1989). 
125 Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A. & Klenk, H.-D. 
Neuraminidase is important for the initiation of influenza virus infection in human 
airway epithelium. Journal of virology 78, 12665-12667 (2004). 
 
   
77 
126 Camacho-Pereira, J. et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial 
Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism 23, 1127-1139, 
doi:http://dx.doi.org/10.1016/j.cmet.2016.05.006 (2016). 
127 Barbosa, M. T. P. et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2. 2.5) is 
necessary for the development of diet-induced obesity. The FASEB Journal 21, 3629-
3639 (2007). 
128 Neidich, S. et al. The effect of BMI on the immunoglobulin subclass response to 
influenza vaccination (382.1). The FASEB Journal 28, 382.381 (2014). 
129 Wu, C.-L., Diekman, B. O. C., Jain, D. & Guilak, F. Diet-induced obesity alters the 
differentiation potential of stem cells isolated from bone marrow, adipose tissue, and 
infrapatellar fad pad: The effects of free fatty acids. International journal of obesity 
(2005) 37, 1079-1087, doi:10.1038/ijo.2012.171 (2013). 
130 Stout, R. D., Suttles, J., Xu, J., Grewal, I. S. & Flavell, R. A. Impaired T cell-mediated 
macrophage activation in CD40 ligand-deficient mice. J Immunol 156, 8-11 (1996). 
131 Fehniger, T. A. et al. CD56bright natural killer cells are present in human lymph nodes 
and are activated by T cell-derived IL-2: a potential new link between adaptive and 
innate immunity. Blood 101, 3052-3057, doi:10.1182/blood-2002-09-2876 (2003). 
132 Ni, K. & O'Neill, H. C. The role of dendritic cells in T cell activation. Immunol Cell Biol 75, 
223-230, doi:10.1038/icb.1997.35 (1997). 
133 Centers for Disease, C. & Prevention. Estimates of deaths associated with seasonal 
influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep 59, 1057-1062 
(2010). 
134 Morgan, O. W. et al. Morbid obesity as a risk factor for hospitalization and death due to 
2009 pandemic influenza A(H1N1) disease. PLoS One 5, e9694, 
doi:10.1371/journal.pone.0009694 (2010). 
 
 
 
 
 
 
 
